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Abstract:  The research and development of new electronic-nose applications in the 
biomedical field has accelerated at a phenomenal rate over the past 25 years. Many 
innovative e-nose technologies have provided solutions and applications to a wide variety 
of complex biomedical and healthcare problems. The purposes of this review are to present 
a comprehensive analysis of past and recent biomedical research findings and 
developments of electronic-nose sensor technologies, and to identify current and future 
potential e-nose applications that will continue to advance the effectiveness and efficiency 
of biomedical treatments and healthcare services for many years. An abundance of 
electronic-nose applications has been developed for a variety of healthcare sectors 
including diagnostics, immunology, pathology, patient recovery, pharmacology, physical 
therapy, physiology, preventative medicine, remote healthcare, and wound and graft 
healing. Specific biomedical e-nose applications range from uses in biochemical testing, 
blood-compatibility evaluations, disease diagnoses, and drug delivery to monitoring of 
metabolic levels, organ dysfunctions, and patient conditions through telemedicine. This 
paper summarizes the major electronic-nose technologies developed for healthcare and 
biomedical applications since the late 1980s when electronic aroma detection technologies 
were first recognized to be potentially useful in providing effective solutions to problems 
in the healthcare industry. 
OPEN ACCESSSensors 2011, 11                                       
 
1106




Rapid progress in the advancement of several key science areas including artificial intelligence, 
digital electronic sensors design, material sciences, microcircuitry design, software innovations, and 
electronic systems integration has stimulated the development of electronic sensor technologies 
applicable to many diverse areas of human activity. The conceptualization and production of electronic 
nose devices (initially called artificial noses) [1], improved and evolved since the early 1980s to mimic 
mammalian olfactory systems [2-4], have resulted in the creation of a remarkable new sector of sensor 
technology (generally referred to as artificial olfaction [5]) that has exploded with the production of 
many new potential applications largely resulting from the invention of numerous new types of 
olfactory-competent electronic sensors and sensor arrays. These sensor devices, termed electronic 
noses by Gardner and Bartlett [6] in 1994, are capable of detecting, identifying, and discriminating 
many types and sources of a wide diversity of chemical species and mixtures of compounds present in 
headspace volatiles of sampled air (derived from any source), including volatile organic compounds 
(VOCs) most commonly produced and released from such organic sources as living microbes and 
multicellular organisms. Recent advances in electronic-nose (e-nose) technologies, based on many 
different electronic aroma detection (EAD) principles and mechanisms [7], have made possible the 
development of a wide variety of new e-nose applications that have proven useful in a range of diverse 
commercial industries, including the agricultural, cosmetics, environmental, food, manufacturing, 
military, pharmaceutical, and regulatory sectors, and in many fields of applied sciences [8]. Advances 
in the use of electronic-nose instruments in biomedical applications are no exceptions. In fact, the 
development of e-nose applications in the healthcare industry arguably has grown more rapidly than 
any other industry due to higher available capitalization for products development in the healthcare 
industry, and greater economic incentives for the development and use of cheaper, high-performing 
electronic-sensor instruments. Greater demands on improvements in performance, effectiveness and 
lower costs of biomedical tools and instruments used in daily healthcare applications, also have 
resulted from increasing limitations on financial and physical resources as a consequence of increasing 
healthcare costs, budgetary cuts or constraints, changes in socio-economic factors and healthcare 
legislation, and increasing globalization of world economies that has allowed the sharing of 
technologies as a result of improved communications. Increasing demands on functional requirements 
of biomedical tools and machines has necessitated the development and application of new more 
efficient and intelligent diagnostic and aroma-mensurative devices that provide rapid and accurate 
qualitative and/or quantitative results with large-sample throughput and consistently-accurate results 
despite repeated use. 
The characterization of abnormal chemical compounds associated with human diseases, particularly 
microbial volatiles of pathogenic origin, has been keenly investigated since the development of gas 
chromatography (GC) and mass spectroscopy (MS) instruments. Davies and Hayward [9] identified Sensors 2011, 11                                       
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acetylcholine and proposed that it may be a precursor of trimethylamine, a possible early biochemical 
marker of urinary tract infections caused by Proteus and Klebsiella species. Grametbauer et al. [10] 
investigated the metabolic profiles of 189 strains of 33 bacterial species and found a wide diversity of 
volatile compounds was produced. They concluded that it was not possible to completely differentiate 
between strains of a species even when the volatile profiles showed distinct peaks. GC-MS analysis of 
VOCs from pathogenic bacteria such as Pseudomonas aeruginosa,  Proteus mirabilis,  Klebsiella 
pneumoniae, Staphylococcus aureus, and Clostridium septicum revealed that all of them produced 
complex odor patterns [11]. Similar results were reported from extensive studies of lactic acid-bacteria 
using GC techniques to distinguish between Leuconostoc,  Pediococcus, and Lactobacillus  
species [12]. Mayakova et al. [13] developed a GC-MS method to analyze volatile fatty acids to detect  
post-operative infections caused by non-clostridial anaerobes in abdominal and gynecological surgery. 
Even though GC-MS analyses have enabled comprehensive studies and identifications of possible 
disease markers, these tools have not emerged as routine instruments for clinical diagnosis due to 
associated high operating costs, laborious and time-consuming sample-preparation methods, and 
requirements for significant training and expertise for effective operation and data 
interpretation  [14,15]. In addition, the high complexity of volatile profiles detected using GC-MS 
methods precludes the ability to easily associate these chemical profiles to specific microbial or biotic 
sources because chemical profiles (unlike aroma profiles) are not considered as a whole in data 
analyses, for these instruments are designed to identify individual chemical compounds, not identify 
the complex sample mixture as a whole unit. GC-MS instruments have been very useful in facilitating 
our understanding of the biochemistry of human diseases and disorders, and identifying aberrant 
VOCs that may serve as diagnostic biomarkers of specific diseases and physiological or genetic 
disorders, but uses of these instruments should be limited to applications for which they   
were designed.  
The limited applicability of GC-MS and similar analytical instruments in clinical diagnoses has 
prompted the need to develop simpler, cheaper, and more user-friendly diagnostic instruments for 
routine clinical applications. The invention of electronic noses made it possible, for the first time, to 
produce application-specific instruments that fulfill the needs of clinical requirements for routine use. 
For example, disease-diagnosis applications of e-noses provide the capabilities to more cheaply 
identify microbes from their precise mixtures of VOC headspace metabolites (including individual 
disease biomarkers) without having to identify all chemical species present in these usually complex 
mixtures. Each complex mixture of VOCs in a sampled headspace, derived from cultures or samples of 
a particular microbe, can be effectively associated with that specific microbial species through the 
recognition of a unique electronic aroma signature pattern (EASP), or aroma profile, that is exclusively 
associated only with that microbe (or even a specific strain), and predetermined in library recognition 
files that are produced and previously recorded from sensor outputs of the e-nose sensor array using 
known reference samples of various microbial species to produce a library of aroma profiles stored in 
corresponding databases [7]. 
Electronic-nose devices offer many potential uses and advantages for numerous biomedical 
applications as a result of a wide range of different operating principles associated with various e-nose 
instrument types and designs. The major strengths of e-nose devices are their versatile capabilities 
afforded by the potential abilities of developers to produce low-cost tools for particular applications Sensors 2011, 11                                       
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with customized instrument designs with specific use-requirements, the high variety of individual 
sensors available for selection (from large sensor libraries) in designing instrument sensor arrays for 
specific applications, and the wide diversity of useful medical information that can be derived from 
aroma measurements and analyses of air samples obtained directly from human tissues, biopsies, or 
cultures. The following review thoroughly explores many of the most important and useful 
applications that electronic-nose applications offer to the healthcare and biomedical fields, including 
some exciting new potential applications derived from recent research findings of scientists throughout 
the world. 
2. History of Aroma and Electronic Noses in Biomedicine 
The use of unusual human odors or aromas as indicators of disease probably originated with 
Hippocrates, the father of medicine, around 400 BC [16]. A common diagnostic practice during that 
time was to pour human sputum on hot coals to generate a smell that provided some indication of 
human ailments. Traditional Chinese medicine also employed the power of olfactory diagnosis [17]. 
Even though these practices were used long before the development of the germ theory of disease, 
early medical practitioners clearly recognized that the presence of human diseases could change the 
odor of bodily excretions, including sweat, urine, vaginal fluid, and sputum. Liebig and Woehler [18] 
described the production of benzaldehyde by microorganisms in the early 19th century. The final 
connection between the foul odors of infected wounds and very similar odors produced in cultures of 
pathogenic bacteria, causal agents of many microbial diseases, was realized some time after conclusive 
proofs of the germ theory were demonstrated by Robert Koch in 1876 [19], based on experiments 
conducted on anthrax, the human and cattle disease caused by the bacterium Bacillus anthracis. 
Omelianski [20] reported naturally-liberated microbial odors associated with the accumulation of 
staling metabolic products such as organic acids and alcohols in cultures of Mycobacterium 
tuberculosis and Pseudomonas aeruginosa. 
2.1. Early Uses of Descriptive Aromas in Healthcare Applications 
Diagnosing human diseases based on the sense of smell, in addition to physical examinations, 
remained one of the most reliable methods used in bedside medicine for many years. The odors 
emitted by patients was once considered among the first major clues leading to an early diagnosis. The 
practice of evaluating effluvia (odor of patients), along with other extracorporeal information, was 
regarded with such importance that Fitzgerald and Tierney [21] (in 1982) summarized a range of 
different types of extracorporeal observations (clues) and supplemental diagnostic techniques that 
provided useful physical evidence for clinical diagnostic evaluations. They were most concerned that 
the art of olfactory and extracorporeal diagnosis would be lost to the next generation of physicians 
largely due to the lack of attention to and emphasis on application of these skills in contemporary 
office practice. To emphasize the value of preserving olfactory methods in the medical profession, they 
provided a number of different examples of aroma bioindicators for various types of disease. Other 
examples of descriptive aromas have been documented in numerous reports that associate connections 
between unusual specific human odors (or aromas) and particular human diseases and disorders. A list 
of some of these descriptive aromas that have been reported as positive indicators of specific diseases, Sensors 2011, 11                                       
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physiological or metabolic disorders, and genetic anomalies are presented in Table 1. The long history 
of human odors being used for disease diagnosis by medical doctors attests to the usefulness and 
effectiveness of olfactory information in providing valuable clues for assessing patient conditions, and 
to the ingenuity and skill of medical practitioners in achieving accurate diagnoses without the aid of 
modern analytical equipment and chemical-detection devices now available for this purpose. 
Table 1. Some early uses of descriptive aromas in diagnosing specific diseases and 
metabolic disorders associated with odors released from affected human tissues. 
Disease/ Disorder  Body source  Descriptive aroma  References 
Acromegaly Body  Strong,  offensive  [22] 
Anaerobic infection  Skin, sweat  Rotten apples  [23] 
Azotemia (prerenal)  Urine  Concentrated urine odor  [24] 
Bacterial proteolysis  Skin  Over-ripe Camembert  [23] 
Bacterial vaginosis  Vaginal 
discharge  Amine-like [23] 
Bladder infection  Urine  Ammonia  [23] 
Bromhidrosis Skin,  nose  Unpleasant  [25] 
Darier’s disease  Buttocks  Rank, unpleasant odor  [26] 
Diabetic ketoacidosis  Breath  Rotting apples, acetone  [26,27] 




Dimethyl sulfide  [28] 
Cystic fibrosis  Infant stool  Foul  [23] 
Diabetes mellitus  Breath  Acetone-like  [23] 
Diphtheria Sweat  Sweet  [23,26,29] 
Empyema (anaerobic)  Breath  Foul, putrid  [29] 
Esophageal diverticulum  Breath Feculent,  foul  [26,29,30] 
Fetor hepaticus  Breath  Newly-mown clover, sweet  [29] 
Gout Skin  Gouty  odor  [26] 
Hydradenitis suppurativa  Apocrine sweat 
glands  Bad body odor  [26] 
Hyperhydrosis  Body  Unpleasant body odor  [26] 
Hyperaminoaciduria (Oast-
house Syndrome)  Infant skin  Dried malt or hops  [26,31] 
Hypermethioninemia Infant  breath  Sweet, fruity, fishy, boiled 
cabbage, rancid butter  [23,26,29] 
Intestinal obstruction  Breath  Feculent, foul  [26,29,30] 
Intranasal foreign body  Breath Foul,  feculent  [23,29,30] 
Isovaleric acidemia  Skin, sweat, 
breath  Sweaty feet, cheesy  [23,29,32,33] 
Ketoacidosis (starvation)  Breath  Sweet, fruity, acetone-like  [29] 
Liver failure  Breath  Musty fish, raw liver, feculent, 
mercaptans, dimethyl sulfide  [28,29] 
Lung abscess  Sputum, breath Foul, putrid, full  [23,26,29,30] 
Maple syrup urine disease  Sweat, urine, 
ear wax  Maple syrup, burnt sugar  [23,26] 
Phenylketonuria Infant  skin  Musty, horsey, mousy, sweet 
urine  [17,23,26] 
Pneumonia (necrotizing)  Breath  Putrid  [23] 
Pseudomonas infection  Skin, sweat  Grape  [23] 
Renal failure (chronic)  Breath  Stale urine  [27] 
Rotavirus gastroenteritis  Stool  Full  [23] 
Rubella  Sweat  Freshly plucked feathers  [23] 
Schizophrenia Sweat  Mildly  acetic  [34,35] Sensors 2011, 11                                       
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Table 1. Cont. 
Disease/ Disorder  Body source  Descriptive aroma  References 
Scrofula Body  Stale  beer  [26] 
Scurvy Sweat  Putrid  [26] 
Shigellosis Stool  Rancid  [23] 
Smallpox Skin  Pox  stench  [26] 
Squamous-cell carcinoma  Skin Offensive  odor  [36] 
Sweaty feet syndrome  Urine, sweat, 
breath  Foul acetic  [37] 
Trench mouth  Breath  Halitosis  [29] 
Trimethylaminuria Skin,  urine  Fishy  [23] 
Tuberculosis lymphadenitis  Skin  Stale beer  [23] 
Tubular necrosis (acute)  Urine  Stale water  [24] 
Typhoid  Skin  Freshly-baked brown bread  [23,26,29] 
Uremia  Breath  Fishy, ammonia, urine-like  [29] 
Vagabond’s disease  Skin  Unpleasant  [26] 
Varicose ulcers (malignant)  Leg  Foul, unpleasant  [38-40] 
Yellow fever  Skin  Butcher’s shop  [26,29] 
 
Some genetic disorders, caused by defects in amino acid metabolism, have been associated with 
particular, unusual smells. For example, certain hereditary metabolic diseases in children may be 
associated with specific odors in their excrement [41]. Maple syrup urine disease (MSUD) is a 
metabolic disorder caused by a gene defect that prevents the body from breaking down certain amino 
acids such as leucine, isoleucine, and valine through normal oxidative decarboxylation. This condition 
leads to a buildup of these amino acids in the blood. Persons with MSUD may produce urine that 
smells like maple syrup [23,26]. Similar diseases caused by enzyme deficiencies have a distinctive 
odor due to the accumulation of undecomposed metabolites in the body. Pediatricians have long 
associated phenylketonuria (PKU) in children with a mousy or barny smell in the urine [28]. 
Phenylketonuria is an inherited metabolic disorder caused by a deficiency of the specific enzyme 
phenylalanine hydroxylase (PAH). In the homozygous patient with PKU, their inability to synthesize 
PAH (in an active form) leads to hyperphenylalanineaemia and phenylpyruvic aciduria due to the 
failure to break down phenylalanine. Without the enzyme, levels of phenylalanine and closely-related 
compounds build up in the body to toxic levels. These substances are harmful to the central nervous 
system and can cause brain damage. Phenylacetic acid in sweat and urine produces a musty odor 
resembling sweaty locker-room towels [26]. Hypermethioninemia, due to deficiency of the enzyme  
S-adenosylhomocysteine hydrolase that causes abnormal handling of methionine, can produce a 
characteristic odor in the urine, sweat and breath that in some cases is sweet and in other cases likened 
to boiled cabbage [26]. Tanaka et al. [32] described the disease isovaleric acidemia of infants who 
emitted a smell similar to sweaty feet, owing to the accumulation of isovaleric acid caused by an 
enzymatic block in leucine metabolism. Other genetic disorders of amino acid metabolism, including 
histidinemia, cystinuria and tyrosinemia, cause the production of volatile oxidized amino-acid 
derivatives that may be detected by unusual odors in the human breath [42]. 
Several physiological orders also may be diagnosed by unusual body odors. Acromegaly, a chronic 
metabolic disorder caused by the production of excessive human growth hormone (HGH) by the 
pituitary gland leading to gradual enlargement of body tissues, is sometimes associated with a strongly 
offensive body odor and often accompanied by increased sweating and oily skin [22]. Sensors 2011, 11                                       
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Trimethylaminuria (TMAU) is a hereditary metabolic disorder in which an individual is not able to 
convert trimethylamine into a compound called trimethylamine N-oxide. Trimethylaminuria is also 
known as fish odor syndrome or fish malodor syndrome due to the fishy odors that result from the 
accumulation of trimethylamine in the urine or volatilization after release from the skin [23]. Azotemia 
is a condition where the patient’s blood contains uncommon levels of urea, creatinine, and other 
compounds rich in nitrogen [24]. Prerenal azotemia is the most common form of kidney failure in 
hospitalized patients. Any condition that reduces blood flow to the kidney may cause it. The 
accumulation of these nitrogen-rich compounds in the urine results in a very strong concentrated 
ammonia-like urine smell. Certain diseases causing liver failure and chronic congestive heart failure of 
portcaval shunts have been associated with the characteristic odor of dimethyl sulphide [28]. 
Some infectious diseases are well known for causing the production of diagnostic odors in afflicted 
patients. The distinctive stench odor of smallpox was very familiar to physicians dealing with this 
disease during the epidemics of the past. Patients with typhoid fever produce a smell comparable to 
freshly baked brown bread, whereas individuals with diphtheria have a sweet odor [26]. Diseases such 
as squamous cell carcinoma and yellow fever release malodorous compounds from the skin [26,29,41]. 
Patients with yellow fever have an odor that resembles a butcher shop [26,29]. Scrofula, an infectious 
disease more precisely known as cervical tuberculous lymphadenopathy (tuberculosis of the neck), is 
caused by the bacteria Mycobacterium tuberculosis in adults, but in children it is usually caused by 
Mycobacterium scrofulaceum. Patients with scrofula emit a fermentative odor similar to stale beer. 
Unpleasant characteristic smells frequently are produced from certain respiratory tract diseases 
including bronchiectasis, lung abscesses, and ozaena. Osteomyelitis, uraemia, and Fröhlich’s 
syndrome have been reported to generate characteristic odors [26]. Vincent’s angina, gingivitis, and 
tonsillitis also may yield smells that are recognizable by the well-trained diagnostician [21,26]. 
A few common noninfectious diseases and conditions have been associated with characteristic 
odors. Gout is a chronic form of arthritis that is caused by high uric acid levels in the blood which 
accumulate and build-up to painful levels in the tissues and joints. Sweat from a gout patient yields a 
particular sweet odor. By contrast, scurvy victims who have an acute vitamin C (ascorbic acid) 
deficient are said to produce sweat that has a putrid odor [26]. Starvation victims with ketoacidosis 
generally have a sweet, acetone-like breath due to elevated levels of ketone bodies in the blood. 
Ketones are formed when glycogen stores in the liver have run out due to starvation and the body 
switches to fat metabolism that generates ketones as breakdown products from fat stores for energy 
production [29]. 
The ingestion of certain inorganic chemicals, poisons and drugs can produce peculiar breath odors 
that are indicative of the substances ingested. For example, amphetamine drug abuse can cause a 
certain type of bad halitosis [21,26]. Human breath with a garlic-like smell may suggest ingestion of 
penicillin [21], parathione [26], arsenic, tellurium, or selenium [43]; or acute oral poisoning with 
yellow phosphorus [44]. Cyanide ingestion is indicated by a bitter-almond breath odor [21], whereas a 
fruity penetrating breath odor is common for chloral hydrate or paraldehyde ingestion [26]. Turpentine 
poisoning is suggested by the odor of violets in the urine [26], whereas a urine odor that smells like 
stale water is indicative of acute tubular necrosis, but urine with a concentrated ammonia smell is more 
likely due to prerenal azotemia [24]. Sensors 2011, 11                                       
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Acute exposure to VOCs through skin contact, ingestion, or inhalation often can be detected in the 
breath within 6–12 hours after exposure [14]. Some of these have diagnostic odors including diethyl ether, 
dimethyl sulfoxide, isobutane, tetrachloroethane, trichloroethane, and trichlorotrifluoroethane [45-50]. 
Disulfiram is typically metabolized and converted into carbon disulfide that is detectable in the   
breath [51]. Chemical exposure cannot be detected in the breath for many other compounds because 
they are either decomposed by the liver or eliminated by excretion or exhalation. Schiffman and 
Williams [52] clarified that unpleasant odors, such as are detected in the breath, are warning signs of 
chemical exposure and that the exposure to odorants (compounds with odor properties) cause the 
damage rather than the odor itself. Thus, the odor sensation simply serves as an exposure marker. 
2.2. Biological Olfaction 
Experiments and observations in the area of biological olfaction were necessary and important steps 
in the evolutionary process toward developing tools for aroma-detection applications in medicine. 
Before the invention of electronic noses, the olfactory systems of various animals were originally 
investigated as a means to detect disease in human patients. The domesticated dog was often used due 
to a keen sense of smell and the ability to discriminate not only faint odors, but also distinguish small 
differences in odors [8]. Various claims and unofficial reports describing incidences of family pets 
sensing unusual odors in their human owners were not uncommon. The beginning of interest in testing 
the hypothesis that dogs might be able to detect diseases in humans probably began in 1989 when 
Williams and Pembroke described the case of a woman who was encouraged to get a skin lesion 
sniffed by a dog that showed inordinate interest in a spot on her skin [53]. The lesion proved to be a 
malignant melanoma after clinical examination. A paper published by Pickel et al. [54] provided initial 
results indicating that the hypothesis suggested by Williams and Pembroke might be valid. Subsequent 
studies have further demonstrated the feasibility that a dog’s sense of smell can detect certain human 
cancers in the bladder [55], lung and breast [56], prostate [57], and ovaries [58]. 
Moser and McCulloch [59] conducted a systemic review of research on canine detection of human 
cancers and concluded that dogs can detect human cancers with enough sensitivity and specificity to 
be useful for diagnostic purposes. They thought canine scent detection was a valid and feasible method 
for cancer detection, but suggested that exhaled breath seemed to be a better non-invasive biological 
sample than urine for cancer biomarker analysis and early diagnosis of certain cancers. Indeed, more 
biomarkers of cancer and other diseases have been found in the breath than in any other sample type 
(see Section 4.1). 
Attempts to bridge the gap between biological (living) olfaction systems and artificial olfactory 
systems (using the electronic nose) are underway in numerous research laboratories throughout the 
world. Many researchers have taken the approach of “bioinspired” sensor design by attempting to 
mimic natural biological olfactory systems. Wyszynski and Nakamoto [60] reviewed available   
gas-sensing technologies and found the Surface Acoustic Wave (SAW) type sensor arrays, including 
the Quartz Crystal Microbalance (QCM) sensors, were the most suitable choices for artificial olfaction 
in their opinion, based on sensor design and operating principles. They provided basic information on 
the structure and principles of various biological and artificial olfactory systems along with methods 
for the fabrication of biomimetic or bioinspired sensor arrays to develop QCM electronic noses. Sensors 2011, 11                                       
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2.3. The Discovery of Bio-Indicators of Disease 
The invention of Gas Chromatography (GC), during the 1950’s and early 1960’s, and GC-linked 
with Mass Spectrometry (GC-MS) in subsequent years provided the necessary instrumentation to 
begin to separate and identify individual volatile biomarkers of human diseases. However, one of the 
biggest early problems with VOC analyses was that it was difficult to capture bioindicator compounds 
from sample sources of diseased tissues due to the high volatility of gaseous components that allowed 
escape to the air. An apparatus for sampling volatile skin vapors for GC analysis was devised in 1973 
by Distelheim and Dravnieks [61]. This sample-collection apparatus was an early precursor to modern 
techniques and devices such as chemical trapping, cryogenic trapping, and adsorption trapping by 
Solid Phase Microextraction (SPME) apparati used to capture VOCs from the gaseous state for 
chemical analysis. The technique of cryogenic trapping was developed in 1971 by Linus Pauling who 
constructed a cold trap chilled with liquid nitrogen for human-urine volatiles, and a stainless steel tube 
cooled in an isopropyl alcohol-dry ice bath for human-breath volatiles to freeze out VOCs that were 
then revolatilized by heating when injected into the gas chromatograph [62]. Since then, thousands of 
VOCs have been identified in human breath, but the biochemical significance of most of these 
compounds is still largely unknown [63,64]. 
Breath tests were used by physicians from the earliest history of medicine because it was known 
that the odor of the breath could be altered in individuals with certain diseases [15]. Susruta Samhita, 
one of the originators of ancient Hindu medicine around 600 BC and the father of modern surgery, 
recognized the importance of the peculiar smells in the breath and perspiration for identifying many 
diseases [65]. Some breath aromas have been determined to be highly characteristic of specific diseases. 
For example, patients with diabetic ketoacidosis smell like rotten apples, mainly due to acetonemia, and 
chronic renal failure that causes the breath to smell like stale urine [27]. Phillips et al. [66] investigated 
VOCs in breath as possible tumor markers for lung cancer and found two classes of compounds, 
mainly alkanes and monomethylated alkanes, in lung cancer patients which were absent in healthy 
individuals. A similar study was conducted by essentially the same research team to investigate the 
presence of VOCs as markers for breast cancer [67]. Inflammatory lung diseases such as asthma, 
Chronic Obstructive Pulmonary Disease (COPD), and cystic fibrosis also have been associated with 
specific volatile markers, including nitric oxide and various hydrocarbons, in exhaled breath [68,69]. 
Numerous studies have elucidated specific biomarker indicator VOCs, associated with various 
diseases, using a range of different chemical techniques in addition to GC and GC-MS [70].   
Hiroshi et al. [71] found trace amounts of two volatile sulfur-containing compounds, methyl 
mercaptan and dimethyl sulfide, in expired alveolar gas by GC-flame photometric detection (FPD) and 
GC-flame ionization detector (FID) analysis in 116 total subjects with acute and chronic hepatitis, 
hepatic cirrhosis, and stomach ulcer and/or biopsy of gastric mucosa. Goldberg [72] used capillary 
GC-FID and MS to identify VOCs in blood plasma and cerebrospinal fluids of human subjects 
suffering from hepatic encephalopathy. Of 40 VOCs detected, 21 were identified and only   
3-methylbutanal was found to be significantly elevated (P  < 0.01) in chronic encephalopathics 
compared to controls. The concentration of this 3-methylbutanal increased with severity of the 
encephalopathic state. Sensors 2011, 11                                       
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Ondrula et al. [73] utilized a rodent-colitis model to demonstrate that pentane generation and 
exhalation increased by membrane lipid peroxidation after induction of colonic inflammation by 
oxygen radicals. They used GC-analysis to show that pentane levels in exhaled air were correlated 
with damage resulting from oxygen radicals that played a key role in colitis. In this case, the pentane 
released in expired breath was generated by lipid peroxidation of omega-6 polyunsaturated fatty acid. 
They found the most deleterious effects of lipid peroxidation on cell membranes were perturbations of 
membrane fluidity and calcium transport capacity. Formation of free oxygen radicals and subsequent 
cellular peroxidation of lipids have been implicated in the inflammatory induction of cellular damage 
seen in many other medical conditions. By contrast, Garner et al. [74] analyzed the VOC profiles from 
feces of colitis subjects using GC-MS to identify possible volatile patterns (specific mixtures) that 
could be used to diagnose gastrointestinal disease. A total of 297 volatiles were identified with certain 
compounds (ethanoic, butanoic, pentanoic acids, benzaldehyde, ethanol (acetaldehyde), carbon 
disulfide, dimethyldisulfide, acetone, 2-butanone, 2,3-butanedione, 6-methyl-5-hepten-2-one, indole, 
and 4-methylphenol) that were found in all samples. Forty-four compounds were shared by 80% of 
subjects. When compared to healthy donors, volatile patterns from feces of patients with ulcerative 
colitis, Clostridium difficile and C. jejuni infections, were all significantly different. 
Research pursuits of bioindicator VOCs in human breath have been the most popular and common 
approach to disease detection due to the ease with which samples can be noninvasively collected, and 
the theoretical high probability that many aberrant volatile compounds generated by disease within the 
body are eventually expelled out of the body through the lungs. A wide variety of different chemical 
analyses have been used to search for bioindicators of disease in the breath of humans and model 
mammalian systems. Mottram et al. [75] demonstrated the feasibility of an early detection of 
hyperketonaemia in dairy cows by monitoring concentrations of acetone in the breath and ketones in 
the milk. Ketosis onset could be detected by GC-MS long before clinical signs (inappetance and a 
weakened state) became apparent. Likhodii et al. [76] found that they could monitor systemic ketosis 
induced by maintenance of a high-fat, low-carbohydrate ketogenic diet (KD) by measuring breath 
acetone using GC-FID analysis. They were able to validate the breath-acetone test as a fast, reliable, 
and noninvasive tool for ketosis assessment suitable for clinical studies of KD for alleviating   
drug-resistant epilepsy. Lord et al. [77] used GC-Ion Mobility Spectrometry (GC-IMS) to investigate 
acetone and ethanol as biologically important markers of human health and exposure to hazardous 
VOCs. Karl et al. [78] measured human breath VOCs using Proton-Transfer Reaction Mass 
Spectrometry (PTR-MS) to study the relation between isoprene concentration in the breath and blood 
cholesterol level. Amann et al. [79] utilized PTR-MS for online monitoring of VOC-emission patterns 
over time during sleep, combined with polysomnography, and in patients suffering from carbohydrate 
malabsorption. Moser et al. [80] employed PTR-MS to determine mass spectrometric characteristics of 
an “average patient sample” to use as possible reference values for comparisons with future patients. 
Research of Selected Ion Flow Tube Mass Spectrometry (SIFT-MS), a relatively new technique for 
real-time quantification of trace VOC gases in breath, has elucidated several potential medical 
applications by detecting volatile bioindicator compounds [81-89]. 
Optical Absorption Spectroscopy (OAS) has been used to assess oxidative stress for a range of 
clinical applications including a wavelength-modulation system that measures ethane in breath [90], 
and a mid-infrared (IR) high-resolution Tunable Laser Absorption Spectroscopy (TLAS) system to Sensors 2011, 11                                       
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measure exhaled nitric acid and carbon dioxide in human breath [91,92]. Baum et al. [93] reported use 
of Ultraviolet Absorption Spectroscopy (UVAS) to measure acetylene in breath for monitoring cardiac 
output. Wang et al. [94,95] developed laser spectroscopic techniques and a portable breath analyzer 
based on Cavity Ringdown Spectroscopy (CRS), operating at ultraviolet and near-IR frequencies, to 
detect acetone in breath. 
Colorimetric methods previously were used to measure specific VOCs in human breath, including 
acetone and hydrogen cyanide [96-98]. Teshima et al. [96] applied colorimetric methods to determined 
acetone in breath by reaction with alkaline salicylaldehyde to form a colored product monitored with 
GaN-based Light Emitting Diodes (LEDs) by blue-light emission at 465 nm. Corradi et al. [99] 
assayed nitrate (NO3
-) in Exhaled Breath Condensate (EBC) from patients with different inflammatory 
airway diseases using ion chromatography followed by conductivity measurement using ion 
chromatography. Nitrate levels were elevated compared to controls in smokers, asthmatics, and 
patients with Community-Acquired Pneumonia (CAP), but not in patients with Chronic Obstructive 
Pulmonary Disease (COPD). Balint et al. [100] used a chemiluminescence analyzer to discover that  
3-nitrotyrosine, a stable end product from the metabolic oxidation of nitric acid, may be a bioindicator 
of cystic fibrosis (CF). Nitrotyrosine levels in breath condensate were increased significantly in CF 
patients compared with normal subjects. 
Filipiak et al. [101] analyzed VOCs released from a lung cancer epithelial cell line, derived from a 
lung squamous cell carcinoma, by thermal desorption GC-MS. They confirmed that certain VOCs are 
specifically released or consumed by lung cancer cells indicating the presence of a tumor in the lung.  
A significant increase in concentrations of four organic compounds (2,3,3-trimethylpentane,   
2,3,5-trimethylhexane, 2,4-dimethylheptane and 4-methyloctane) were found in the headspace of 
cancer-cell cultures compared to controls after incubation for 18 hours. Brunner et al. [102] applied 
multivariate statistical analysis on 42 selected marker VOCs, emitted by in vitro cultured cancerous 
and noncancerous human cell lines and identified with Proton Transfer Reaction Mass Spectrometry 
(PTR-MS), to clearly distinguish between cancerous and non-cancerous cell lines. Among all of the 
VOCs identified from headspace volatiles of the cell lines, the most outstanding compound was 
acetaldehyde that was absent among headspace VOCs of the cancer cell lines, revealing significant 
consumption by cancerous cells, but not by non-cancerous cells. 
2.4. Summary of E-Nose Reviews of Specialized Biomedical Applications 
We include a brief summary here of some specialized minireviews of electronic-noses that have 
included various categories of applications pertinent to the biomedical field. In some cases, these 
reviews provide additional insights and information beyond what is provided in the current review and 
included additional references in specific aspects of e-nose applications other than the subject 
categories covered here. Manolis [14] provided an early review of literature describing how breath 
metabolites have been used for the diagnosis of disease, including neonatal screening, toxicology, and 
metabolic diseases. Gardner et al. [103] assessed research carried out at Warwick University 
(Coventry, England) to apply an e-nose to the identification of pathogens in cultures and to diagnose 
diseases from breath samples. Thaler et al. [104] evaluated e-nose medical applications such as 
detecting human pathogens in diseased tissues and monitoring various medical conditions.   Sensors 2011, 11                                       
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Lisboa [105] examined the contributions of artificial neural networks (ANN), such as those commonly 
used in combination with e-noses, to the clinical functions of diagnosis, prognosis and survival 
analysis within the medical domains of onchology, critical care, and cardiovascular medicine.  
Turner and Magan [106] gave some future perspectives on how e-noses are likely to play a 
significant role in early disease diagnoses, detection of microbial diseases, and in monitoring disease 
epidemiology. Furthermore, Smith [107] reported on efforts to standardize biomedical terminologies in 
order to allow for the future integration of new diagnostic technologies, such as e-noses, without 
creating confusion in biomedical electronic record keeping. Cao and Duan [108] reviewed a range of 
different diagnostic research methods and techniques for VOC breath analysis including chemical 
sensors and electronic noses. Probert et al. [109] summarized the clinical implications of VOC 
analysis of various biological emanations including stool, breath and blood samples and their 
correlation with gastrointestinal and liver diseases. 
Mahmoudi [110] cited examples of how major advances in gas sensor technology could enhance 
the diagnostic power of e-noses to facilitate global surveillance of disease control and management, as 
well as support of a wide variety of expanding global markets. Voinova [111] summarized current 
trends and theory in the analysis of physical properties of thin films measured with four different types 
of mechanically oscillating sensors: (1) the Quartz Crystal Microbalance with Dissipation (QCM-D) 
monitoring, (2) Surface Acoustic Wave (SAW), (3) Resonators and Magnetoelastic Sensors (MESs), 
and (4) a new class of acoustic wave mass sensors called Thin-Film Bulk Acoustic Resonators 
(TFBARs). Qureshi et al. [112]  described the unique properties and structure of carbon-based 
electrochemical sensors, including carbon nanotubes (CNT), Diamond-Like Carbon (DLC) films, and 
diamond film-based sensors. They summarize the most relevant contributions these sensors have 
provided to the development of e-nose technologies and explain why the properties of CNT sensors are 
extremely attractive for the development of a diversity of sensor types ranging from amperometric 
enzyme electrodes to DNA hybridization biosensors. Recently, a carbon-based sensor fast diagnosis 
method, using non-treated blood assay and amorphous DLC electrodes, was developed for specific 
detection of human liver diseases, such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma 
caused by hepatitis B virus (HBV) [113]. Due to these properties, CNT sensors have been utilized in a 
variety of areas such as electronic, optical, mechanical and biomedical applications [114]. 
Wilson and Baietto  [8] provided a thorough review of theoretical operations, electronic nose 
detection principles and mechanisms, and examples of commercial e-nose applications developed for 
diverse industries. This review includes a limited discussion of biomedical applications of electronic 
noses for human disease diagnoses, and provides some feasibility assessments for new future 
developments of e-nose technologies in biomedicine. Makino and Yano [115] reviewed published 
physiological and computational studies of olfaction to understand how the biological olfactory system 
solves pattern-recognition problems in the real world. Their approach was to address two main issues: 
(1) the mechanism by which odors may activate the olfactory regions of an animal’s brain, and (2) how 
the brain solves problems of recognition in the presence of potentially-confusing background odors 
that may be present in the environment. 
Payne [116] wrote an early review of some e-nose characteristics and developments that led to 
applications in clinical biomechanics. He showed that the ideal e-nose instrument should operate at 
low cost, be non-invasive (not mechanically penetrate the patient’s skin), utilize nonhazardous forms Sensors 2011, 11                                       
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of energy (low energy sources), operate rapidly, provide precise measurements, be reliable (with little 
down time), and be safe for both patient and user. Portability (small size and light weight) was added 
to these characteristics for long-term ambulatory monitoring. Sankaran et al. [117] reviewed a wide 
variety of different electronic instruments and techniques, including electronic noses, which have 
potential phytopathological and biomedical applications. 
3. Applications of Electronic Noses in Biomedicine 
The earliest studies involving aroma measurements for biomedical applications were attempts to 
test the efficacy of using the electronic nose to diagnose human diseases caused by microbial 
pathogens. The initial focus utilized well known pathogenic microorganisms and tested the capability 
of e-noses to identify microbes through the detection of VOCs they released in vitro from bacterial plate 
cultures or directly from infected tissues [118,119]. In 1997, Gibson et al. [120] were able to correctly 
classify human-pathogenic yeasts and twelve different bacteria at a level of 93.4% using an e-nose with a 
16-sensor array and Principal Component Analysis (PCA), a statistical method for comparing headspace 
volatiles of different samples based on the presence of key (principal) components or organic compounds 
present in the volatile mixtures. The same year, Chandiok et al. [121] used a novel artificial nose to 
screen patients for bacterial vaginosis infections, and Wilson and Lester [122] demonstrated the 
feasibility of identifying phytopathogenic microbes based on VOC headspace volatiles released from 
bacterial and fungal cultures. The Cyranose 320 e-nose was used by Dutta et al. [123] to identify three 
different strains of Staphylococcus aureus bacteria responsible for ear, nose, and throat infections in 
hospital patients. They combined PCA based on three-dimensional scatter plots using Fuzzy C Means 
(FCM) and a self-organizing map (SOP) network for data analysis. The Cyranose 320 e-nose was 
capable of identifying three bacterial aroma-subclasses of S. aureus strains with 99.69% accuracy. In a 
similar study, Gardner et al. [124] used a metal oxide semi-conducting (MOS) e-nose to predict the 
growth phase and identity of Escherichia coli and S. aureus. Head space VOCs were examined using a 
sensor array with six MOS sensors and aromas were classified by multi-layer perception (MLP) with a 
back-propagation learning algorithm. MLP identified 100% of unknown S. aureus samples and 92% of 
unknown E. coli samples. The growth phases of the bacteria were predicted from analyses of head 
space samples with an accuracy of 81%. 
3.1. Major Categories of E-Nose Applications in Healthcare 
The early investigations of potential electronic-nose applications for clinical diagnoses and 
pathology eventually led to the realization that the capability of electronically sampling and instantly 
analyzing aromatic volatiles in real time directly from patients (or samples taken from patients) could 
be further exploited to obtain many other types of diagnostic information on medical conditions. The 
resulting list of potential e-nose applications rapidly expanded into many other medical departments. 
The conceptual development of new e-nose applications became theoretically feasible in numerous 
healthcare sectors as new ways were discovered for detecting and monitoring the medical conditions 
of patients from e-nose analyses of sampled air and VOCs in headspace volatiles. Many of these 
discoveries resulted from the identification of biological marker (bioindicator) compounds that were 
correlated with and found to be indicative of specific physiological conditions and diseases. However, Sensors 2011, 11                                       
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the e-nose capability of qualitative chemical detection of specific VOC mixtures also provided uses in 
many other healthcare-related sectors. 
The growth of electronic-nose applications in the healthcare industry has development far beyond 
the initial uses discovered in disease detection. E-nose applications have been forthcoming and 
continue to be developed in a wide diversity of healthcare sectors ranging from prognoses and 
monitoring of various medical conditions to detecting health hazards in the environment, as well as 
applications in pharmacology, research, medical-waste evaluation, and telemedicine (Table 2). 
Numerous specific application areas within each healthcare sector have been discovered and realized 
by the creation of application-specific sensor arrays, odor-recognition algorithms and databases, and 
by the clever identification of carefully-selected target VOCs for detection. 
Wang et al. [130] elucidated the application potential of Cell-based Biosensors (CBBs) to detect 
functional information of biologically active analytes. CBBs have high sensitivity, excellent selectivity, 
and rapid response time. These sensor characteristics have allowed CBBs to be applied to many fields 
such as biomedicine, environmental monitoring and pharmaceutical screening. Recent advances in 
cell-cultured, silicon microfabrication, and genetic technologies promoted dramatic increases in the 
exploration of CBBs. In related work, Wang et al. [131] evaluated the potential of using olfactory and 
taste cell sensors, a type of cell-based biosensor derived from electronic-nose and electronic-tongue 
technologies, to mimic living olfactory and taste cells on the surface of sensor chips such as   
Light-Addressable Potentiometric Sensor (LAPS) to record action potentials representing the odorants 
and taste in olfactory receptor cells within epithelial cell membranes. LAPS semiconductor chips were 
used to test the effects of certain stimulative drugs, norepinephrine (NE) and tetrodotoxin (TTX), to 
elicit action potentials of taste cell and inhibit taste cellular potential, respectively. NE is one of the 
neurotransmitters within taste tissue which elicits action potential in taste cells. They demonstrated the 
feasibility that olfactory and taste cell sensors in the form of LAPS chips could be used to study  
taste-transduction mechanisms to identified ion channels and cell receptors to various drug treatments. 
Table 2. Some major categories of potential electronic-nose applications within various 
sectors of the healthcare and biomedical industries. 
Healthcare sector  Specific application areas  References 
Biochemical tests  Biochemical assays  [125] 
 Blood  compatibility  [126] 
 Cellular-signaling  detection  [127] 
 Clinical  chemistry  [128] 
Biomedical research  Biosensor development  [129-132] 
 Sensory  response  [133-138] 
Chemical exposures  Contact or inhalation of toxic chemicals  [139,140] 
  Biologically-active VOCs, harmful vapors  [141-148] 
  Heavy metal exposure  [149] 
Clinical biomechanics  Culture and in vitro medical analyses  [116] 
Detection  Presence of toxic substances  [150-152] 
Environmental hazards  Health hazards in the environment  [153-155] 
Equipment mechanics  Operational life of healthcare equipment  [156,157] Sensors 2011, 11                                       
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Table 2. Cont. 
Healthcare sector  Specific application areas  References 
Food contaminations  Microbial pathogens or toxins  [158-164] 
 Chemical  contaminants  [165] 
Genetic testing  Presence of genetic anomalies/disorders  [166] 
Immunology Antibody  monitoring  [167,168] 
Infections  Local and systemic infections  [123,169] 
Ingestion of toxins & poisons  Alcohol consumption and abuse  [170] 
  Drug use and abuse  [171] 
 




Microbial culture  Discrimination of types or cell lines  [175] 
  Identification of microbes  [176,177] 
 Growth  phases  [178-180] 
Monitoring  Blood plasma glucose levels  [181-184] 
 Hormone  levels  [185,186] 
  Human tissue activities  [187] 
  Progress of dialysis  [188] 
Organ dysfunctions  Enterogastric reflux  [189] 
 Hearing  loss  [190] 
  Organ failures or abnormalities  [191] 
  Organ transplant success  [192] 
Pathology Cancer  detection  [193] 
  Clinical disease diagnoses  [194,195] 
  Pathogenic microbe detection in tissues  [196,197] 
  Specific pathogen identifications  [198] 
Pharmacology  Drug purity/contaminations, drug toxicoses [8] 
  Drug-delivery controls, drug effectiveness  [199] 
Physical therapy  Prosthetic applications  [200] 
Physiological conditions  Electrophysiological measurements  [201] 
  Hydration, ketosis, oxidative stress  [202,203] 
 Physiological  disorders  [204] 
Respiratory conditions  Oxygen-sensing measurements  [205] 
Remote health care  Telemedicine  [206] 
Waste disposal  Medical waste analysis  [207] 
Wound & graft healing  Bacterial colonization, secondary infection [208] 
  Progress of healing  [209] 
  Skin graft success  [210] 
 
Zhu et al. [136] tested the Fox 4,000 MOS e-nose, equipped with 18 metal oxide sensors and a 
Odorscanner 100 headspace autosampler, for the qualitative and quantitative analysis of flavors in 
pharmaceutical formulations. Flavor analysis is commonly used in drug development to determine 
which flavor additives are most effective in masking drug bitterness and distastefulness in order to 
make oral drug formulations more palatable. Chemometric methodologies including PCA, 
discriminant factorial analysis (DFA), and partial least squares (PLS) were used for data processing Sensors 2011, 11                                       
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and identification. This e-nose technique was used to identify and qualitatively distinguish between 
flavorings of placebo drug formulations. The Fox 4,000 e-nose also was capable of discriminating 
different lots of freshly-prepared and aged flavor samples. These findings confirmed the potential for 
using e-noses to assay flavor concentration during release-testing of oral-solution formulations, and 
monitoring flavor shelf-life in different marketed drug containers. 
Yao et al. [168] compared the performance of aptamer-based and antibody-based quartz crystal 
microbalance (QCM) biosensors for the detection of immunoglobulin E (IgE) in human serum. 
Aptamers and antibodies specific to IgE were immobilized on the gold surface of a quartz crystal and 
frequency shifts of the QCM were measured. The linear range with the antibody was (10–240 μg/L) 
compared to that of the aptamer (2.5–200 μg/L), but a lower detection limit could be observed in the 
aptamer-based biosensor. The reproducibility of the two biosensors was comparable, but the aptamers 
were equivalent or superior to antibodies in terms of specificity and sensitivity. The aptamer receptors 
could tolerate repeated affine-layer regeneration with minimal loss of sensitivity after ligand binding 
and recycling of the biosensor. 
The application of e-nose sensors as physiological-monitoring devices has provided some unique 
opportunities to use them for the control of mechanical treatment-delivery devices such as various 
actuators, valves and pumps. Xu et al. [199] developed a novel conducting polymer drug delivery 
system in which drug release is achieved by electrochemically actuating an array of polymeric valves 
on a set of drug reservoirs. The valves are bilayer structures, made in the shape of a flap hinged on one 
side of a valve seat, consisting of thin films of evaporated gold and electrochemically-deposited 
polypyrrole (PPY). Conducting-polymer (CP) sensors made with PPY have attracted attention because 
of advantages including easy synthesis and microfabrication, low voltage actuation, wide range of 
dopant species, high tolerance to electrode materials and electrolytes, good environmental stability, 
and biocompatibility with physiological environments [211,212]. 
Phillips et al. [192] utilized input data from GC-MS-monitored breath markers of oxidative stress 
that were input into a specialized computer-based mathematical model to predict the probability of 
various grades of heart-transplant rejections. The Breath Methylated Alkane Contour (BMAC), a   
3-dimensional display of the abundance of C4-C20 alkanes and monomethylated alkanes, was 
constructed for every patient. Monitoring with GC-MS is very expensive and time-consuming. Thus, a 
much cheaper and more rapid (real-time) method of VOC analysis of patient breath air, using 
electronic noses in tandem with computers loaded with pattern-recognition algorithms, could be 
achieved once the alkane biomarkers of oxidative stress were known and the corresponding digital 
electronic aroma signature patterns (EASPs) were inserted as reference databases for comparison with 
e-nose input data. EASPs could be integrated into the mathematical-prediction models to determine the 
probabilities of different types of heart-transplant rejections. 
3.2. Detection of Chemical and Biological Contaminants in Food 
The ingestion of food-borne pathogens and associated toxins accounts for a major portion of 
infections caused by pathogenic microorganisms. Detection of the various human pathogens in foods 
prior to consumption provides a very effective means of preventing many gastrointestinal diseases. 
Arora et al. [161] summarized a wide diversity of biomolecular and electronics-based methods, Sensors 2011, 11                                       
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including electronic noses, available for the detection of many food-borne pathogens. The high-speed 
automation of modern food-processing plants has demanded the use of rapid detection systems to catch 
microbial spoilage in food stuffs. The capability of e-noses to rapidly and noninvasively monitor   
food-spoilage VOCs in real-time makes these detectors ideally suited for a range of sanitation and 
safety applications within the food industry, including meat, fish and muscle foods [158]. Currently, 
the food industry is one of the biggest markets utilizing electronic noses for quality assessment of food 
production, inspection of food quality, control of food processes, inspection of meats, monitoring 
fermentation processes, checking for freshness and rancidity, verifying if juice is natural, monitoring food 
and beverage odors, grading the quality of alcoholic beverages, and inspection of beverage containers 
and automated flavor control [213]. Recent studies indicate that electronic nose systems have great 
potential for more effective microbial-contamination control in food-manufacturing processes. 
Microfabrication methods allow biosensors and other automated electrochemical microarray platforms to 
be constructed as arrays and incorporated into lab-on-a-chip devices [128,163]. 
The capability of e-noses to detect toxins and other detrimental microbial metabolites in foods, in 
addition to microbial pathogens, provides another useful application for food safety and disease 
prevention [213]. Rahman et al. [184] indicated that several novel planar interdigital sensors, based on 
interdigital electrode structures such as surface acoustic wave (SAW) e-noses, might be used for the 
detection of marine biotoxins in seafoods. Shellfish toxins and ciguatoxins can cause amnesic shellfish 
poisoning (ASP), azaspiracid shellfish poisoning (AZP), diarrhoeic shellfish poisoning (DSP), 
neurotoxic shellfish poisoning (NSP), and paralytic shellfish poisoning (PSP), while ciguatoxins can 
cause ciguatera fish poisoning (CFP) [214]. A large number of gastrointestinal diseases have been 
linked to the consumption of raw oysters, clams and mussels. Some of these illnesses are related to the 
ingestion of domoic acid-contaminated mussels which lead to ASP [214]. The e-nose detection and 
identification of specific marine biotoxins in foods could prove useful in either prophylactic safety 
procedures to avoid consumption of contaminated foods or to help diagnose the cause of illness 
associated with food poisonings. 
Electronic noses also have been demonstrated to be capable of detecting fungi and fungal toxins 
(mycotoxins) in various types of cereal grains. Paolesse et al. [215] provided evidence for the 
feasibility of the electronic nose in the early detection of fungal VOCs in wheat seeds infected with 
Penicillium chrysogenum and Fusarium verticillioides. The results of two separate studies indicated 
the potential of the PEN2 electronic nose with 10 MOS sensors to detect aflatoxins (produced by 
Aspergillus flavus) in corn, useful for screening grain lots for the presence of toxigenic fungi [162,216]. 
Olsson et al. [159] detected and quantified ochratoxin A and deoxynivalenol in barley grains using 
GC–MS and an electronic nose. Falasconi et al. [160] detected toxigenic strains of Fusarium 
verticillioides in corn with an EOS-835 e-nose using 6 MOS sensors. 
3.3. Detecting Ingestion of Drugs, Alcohol, and Heavy Metals 
Several studies have indicated the potential application of electronic noses for detecting the prior 
ingestion of drugs and alcohol, in cases of substance abuse, and the accidental ingestion of heavy 
metals such as elemental gaseous mercury [149,150,171]. Alcoholism is a growing problem for all age 
groups particularly in advanced countries. The number of illnesses associated with excessive drinking Sensors 2011, 11                                       
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continues to rise and the increased rate of alcohol consumption has lead to increases in the incidence 
of dementia, Alzheimer’s disease, hypertension and cerebrovascular accidents. A recent study by   
Jin et al. [217] was aimed at detecting alcohol concentration (correlated with consumption) and type in 
expired breath air of elderly people. Beer, Japanese sake, red wine and shochu were detected using a  
e-nose sensor array with three types of MOS sensors, adopted to examine the VOC components and 
grade or type of alcohols expired by test subjects. This methodology was used to correctly identify the 
presence and type of alcoholic substance consumed within 1-3 hours after drinking. Comini et al. [150] 
showed that a MOS e-nose with TiO2 films doped with platinum and niobium enhanced sensitivity 
towards ethanol and methanol. Accidental methanol poisoning is still an occasional problem when 
alcohol is consumed from homemade stills. 
3.4. Detecting Hazardous Chemical Presence and Harmful Vapor Exposure 
A variety of tasteless invisible gases including CO, CO2, SO2, NO2, radon, and others are a constant 
threat to human health, particularly in residential homes and in tight living spaces, because these toxic 
gases can build up in the absence of adequate ventilation especially during cold winter months. 
Various commercial smoke detectors and gas sensors are available to detect some of these noxious 
gases, but many other harmful gases that have deleterious effects on human health often go undetected. 
Much of the hazard associated with the less-common, injurious organic gases such as ammonia, 
peroxides, and hydrogen cyanide may be easily detected by an e-nose connected to a centralized 
audible alarm system [142,154]. Indeed, many such systems are being developed for a wide range of 
harmful gases and aerosols [139]. 
Another group of harmful gaseous substances are organic solvents that may be present in ambient air 
within confined air spaces of hospitals and various industrial working environments. These substances 
volatize from many sources including certain plastics, styrofoam and other insulative products, paints and 
varnishes, and open solvent containers. Many e-nose methods have been developed for the detection of 
exposures to toxic and injurious organic solvents such as methanol [141,143], ethanol [144,147], 
chloroform [151], and other hazardous organic gases [146,152]. 
3.5. Detecting Microbes in Potable Water and the Environment 
Potable water resources for drinking and numerous ablutive medical procedures are vulnerable to 
contamination by microbial and chemical agents in the environment. The detection of harmful 
substances in potable water sources is essential to human health. Several research studies demonstrate 
useful e-nose methods for the detection of human pathogens in a variety of environment sources. 
Bastos and Magan [172] used a Bloodhound BH-114 conducting polymer e-nose to detect pathogens 
in seafood and potable water. Similar methods were used to detect microbes in soil and water   
samples [173]. Chang-Yen et al. [205] utilized an optical sensor e-nose to quantify oxygen 
concentration for a variety of applications, including, environmental monitoring, biological respiration 
studies, and cell culture. Oxygen concentration is often indicative of anaerobic conditions in water 
sources with microbial contamination. 
Coliform bacteria are common microbial contaminants of potable water supplies that are located in 
close proximity to sewer lines and sewer discharges into open water supplies and near shallow wells. Sensors 2011, 11                                       
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McEntegart et al. [218] provided evidence that the Moses II e-nose with 8 MOS, 8 QMB, and 4 AGS 
sensors could be used to detect and discriminate between different types of coliform bacteria in 
contaminated samples using pattern recognition of VOCs produced by these microbes during growth. 
This method would be useful to identify the presence of coliform bacteria in water processed from 
major water sources such as open reservoirs often used as drinking water sources for many local 
municipalities and hospitals. 
3.6. Medical Instruments and Waste Evaluation 
Several applications of e-noses are proposed here for checking the sanitation condition of hospital 
instruments, equipment, needles and other biomedical wastes. For example, medical instruments and 
equipment to be used in operations could be checked for contamination by chemicals or microbes, via 
e-nose sniffing for diagnostic VOCs, immediately prior in a medical operation or procedure to assure 
that these critical instruments and equipment have been adequately cleaned and sanitized to avoid 
adverse effects to the patient. Likewise, the presence of hazardous chemicals or contagious microbes 
in biomedical wastes could be tested to make sure such wastes have been properly decontaminated or 
neutralized by autoclaving or other forms of sanitation measures before these medical wastes are 
finally disposed of in sanitary landfills [7,8]. E-noses also could be used to check the gas mixtures of 
anesthetizing agents prior to application to avoid complications caused by altered or improper 
mixtures. All of these pre-emptive safety checks could be quite useful in avoiding unnecessary 
mistakes and complications due to inadequate preparation of materials and equipment prior to medical 
procedures. These measures could potentially save lives and reduce the incidences of malpractice 
associated with negligence resulting from inadequate preventative safety measures or accidents. 
3.7. E-Nose Applications in Remote Telemedicine 
The potential uses of portable electronic noses for medical applications in remote locations (away 
from hospitals) are enormous. Combining advanced telecommunication devices such as 
teleconferencing and videoconferencing with the diagnostic capabilities of e-noses could vastly 
improve the quality of healthcare in remote locations of the world. Practitioners trained in e-nose 
operations could be in direct contact with doctors and specialists in hospitals to determine the health 
condition of ailing patients in the field and administer appropriate treatments. E-nose results could be 
uplinked via satellite, transmitted through fiber-optic phone lines or cable, then output onto the 
computer screens of advising doctors in the hospital [219]. These uses of rapid real-time e-nose 
analytical methods in combination with advanced telecommunication devices are well within the 
capabilities of current technologies. 
Systems for the transmission of medical information from the field have already been developed 
and used in remote locations in Africa [206]. One such system was developed with the capability of 
discriminating patients with diabetic mellitus, gastric tuberculosis and other diseases that cause 
halitosis. Jamal et al. [220] proposed a real-time recognition method using a handheld OMX-GR   
e-nose with an Artificial Neural Network (ANN) analysis system trained with a back-propagation 
algorithm. The identified odors were transmitted electronically from the electronic nose itself (at the 
site of the patient) to doctors or other trained medical personnel at a different location. They also Sensors 2011, 11                                       
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proposed a new method for regenerating the transmitted olfactory information. The combination of 
localized diagnosis using an e-nose and data transmission methods provides a means of extending the 
effective range within which medical doctors can provide services to remote locations of the world. 
4. Disease Diagnosis Using the Electronic Nose 
A major challenge for modern medicine is to achieve effective disease diagnoses through early 
detections of pathogenesis or disease conditions to facilitate rapid corrective or curative treatments, but 
at the same time reduce the invasiveness of diagnostic treatments [8]. Hitherto, the most common 
means of diagnosing most pathological conditions was to conduct chemical analysis of human samples, 
such as breath, blood, urine, sweat, or other bodily fluids. Thus, current clinical diagnoses, based on 
the metabolic profile concept, are largely limited to investigations and examination of human   
fluids [221,222]. Pathogenic microbial species produce a wide range of VOCs. The diagnostic 
potential of pathogen identification through analysis of microbial metabolites was first recognized and 
considered theoretically possible in the early 1960s [223]. Use of traditional VOC chemical analyzers 
such as GC-MS has always been very expensive and too time consuming to allow rapid diagnoses. 
Differences in the aromas of diseased vs. healthy human tissues have provided means for diagnosing 
human pathogenesis and other abnormal health conditions. This correlation has been supported by 
studies using the keen olfactory abilities of well trained dogs whose sense of smell is one million times 
greater than the human nose. Canine olfactory systems have the ability to detect a variety of different 
diseases including melanomas [54], bladder cancer [55], and lung and breast cancers [56]. This 
research provided theoretical evidence of the potential for using electronic noses in disease diagnosis. 
The range of demonstrated applications of electronic noses in the field of clinical medicine have 
included the capabilities of monitoring microbial metabolites released from superficial wounds [224], 
detecting volatiles associated with upper-respiratory tract infections (in rhinology) [225], diagnosing 
disease associated with alterations of VOCs in human breath (such as diabetes) [226], and distinguishing 
cerebrospinal fluid from serum [227,228]. Many other promising diagnostic applications developed for 
the electronic nose have included the detection of ventilator-associated pneumonia [229-231], 
identification of bacterial pathogens [232,233], early screening for the presence of various types of 
cancers [66,234], breath analyses for detection of lung and other organ-related diseases [235], toxin 
exposure [236], and radon ingestion [237]. The following subsections summarize in greater detail 
some of the more promising and useful e-nose applications developed, or under development, in 
different areas of human and in some cases animal (veterinary) disease diagnosis. 
4.1. E-Nose Detection of Chemical Bio-Indicators of Disease 
The use of traditional analytical instruments such as GC-MS to detect biomarkers of disease has not 
become routine for clinical applications largely due to the high cost, high complexity, slow results, and 
difficulty of identifying diagnostic chemical species among a myriad of compounds present in human 
test samples. The need for chemical sensors and instruments containing sensor arrays has become 
increasingly necessary to identify VOCs as simple or complex sample mixtures for disease diagnoses. 
The world-wide demand for intelligent, fast and inexpensive measurement systems for clinical 
diagnosis is increasing. Electronic noses, used for characterizing and identifying complex vapors and Sensors 2011, 11                                       
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aromas, are useful for detections of microbial contamination or diagnosis of infections. Consequently, 
the electronic nose was the logical instrument of choice for disease diagnoses due to the capability of 
identifying complex mixtures of VOCs (as a whole) in addition to individual compounds (in some 
cases) within sampled air using pattern-recognition algorithms. Once VOC biomarkers of disease have 
been identified by tradition chemical means, known pure samples of biomarker compounds and 
mixtures can be prepared and used to develop corresponding pattern-recognition libraries for 
electronic noses that allow the identification of these specific compounds and mixtures associated with 
particular diseases. The collective output from the e-nose sensor array, produced in response to a 
specific group of VOCs (present in the sample air mixture) that come in contact with individual 
sensors in the sensor array, produces a unique Electronic Aroma Signature Pattern (EASP) that is 
unique to that sample mixture [7]. Even changes in the molar ratios of individual component VOCs 
present in a sample mixture give rise to a different e-nose output pattern. Thus, subtle changes in 
physiological processes and metabolic pathways can generate different VOC mixtures and 
correspondingly different EASPs. 
Most of the VOC biomarkers of disease were originally isolated and identified with traditional 
analytical instruments and methods due to the complexity of analyses required to reveal their chemical 
structures. In some cases, a single biomarker compound has been associated with certain diseases and 
metabolic (physiological) disorders, but in other cases a mixture of aberrant compounds has been 
found to be associated with specific diseases. A summary of some important biomarker compounds, 
associated with specific diseases and metabolic disorders, which could be potentially identified with  
e-nose technologies are presented in Table 3. 
Some of the most promising clinical applications being developed using electronic-nose 
technologies have been for the early detection and diagnosis of diseases that can be detected by the 
presence of aberrant VOCs in human breath or expired air. In many cases, disease-associated VOCs 
originate deep within the body in various diseased organs and tissues, but these compounds are 
circulated in the bloodstream and eventually are released from the body mainly through the lungs, but 
also through the urine, feces, and sweat. 
Hundreds of VOCs have been identified in human breath [62], and some of these compounds are 
associated with specific diseases [14,238-239]. As new biomarkers of disease are discovered, use of 
the electronic nose for detection of these biomarker VOCs should become increasingly useful for 
clinical disease diagnoses. Some specific biomarkers that have been identified in association with 
certain human diseases by various research studies are summarized in the following discussion.  
Higher levels of certain alkanes (hexane and methylpentane) have been reported in the breath of 
patients affected by lung cancer compared to patients with healthy lungs [64,66,293].   
Di Natale et al. [283] conducted initial studies to evaluate the feasibility of the e-nose in detecting 
these cancer-marker compounds. They collected breath samples from 35 individuals affected by lung 
cancer, 9 that just had surgical therapy and 18 controls. Two additional individuals were measured 
before and after surgical therapy. The electronic nose successfully detected 100% of lung cancer 
patients, 94% of healthy controls and 44% of post-surgery patients. In this study, an e-nose containing 
eight quartz microbalance (QMB) gas sensors, coated with different metalloporphyrins, was used.  
Yu et al. [294] and Chen et al. [295] confirmed that the QMB e-nose could successfully identify 
eleven diagnostic VOCs that were validated as bioindicators or chemical markers of lung cancer. Sensors 2011, 11                                       
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Table 3. Potential electronic-nose applications for human and animal disease diagnoses via detection of volatile biomarker indicator compounds. 
Disease/Disorder/Infection  Aroma sample source  Associated volatile biomarkers†
  References 
Aerobic gram negative bacteria  Intraperitoneal fluid  Terpenes, ketones  [10] 
Alcoholic fatty liver disease (AFDL)  Human breath  Acetaldehyde, isoprene, 3 other unidentified VOCs  [240] 
Alcohol-induced hepatic injury  Human breath  Ethane, pentane (volatile alkanes)  [241] 
Allograft rejection  Human breath  Carbonyl sulfide  [242] 
Anaerobic bacterial infections  Intraperitoneal fluid  Acetic acid, butyric acid  [243] 
 Urine  Isobutylamine,  acetic  acid, butyric acid  [106,244,245] 
Asthma  Human breath  Pentane, ethane, 8-isoprostane, nitric oxide, 
leukotriene B4, prostaglandin E2 
[246-253] 
Bacteremia  Blood cultures  Specific complex mixture of VOCs  [254] 
  White blood cell cultures  Acetaldehyde, hexanaldehyde  [255] 
Bacterial infections (local)  Human pus  Isobutyric, isovaleric, & isocaproic acids  [256] 
Bacterial vaginosis  Vaginal swabs  Specific complex mixture of VOCs  [257] 
Bacteriuria  Urine  Specific complex mixture of VOCs  [258] 
Breast cancer  Human breath  C4-C20 alkanes, monomethylated alkanes  [67] 
Cardiopulmonary disease Alveolar  air  Ethanol, acetone  [259] 
Cholera Feces  p-menth-1-en-8-ol, dimethyl disulphide [260] 
Chronic hepatitis  Alveolar air  Methyl-mercaptan, dimethyl sulfide  [261] 
Chronic obstructive  
pulmonary disease (COPD) 
Human breath  NO, H2O2, aldehydes, 8-isoprostane, nitrotyrosine, Leukotriene B4, 
cytokines 
[99,100,262-265] 
Cystic fibrosis  Human breath  Leukotriene B4, interleukin-6, carbonyl sulfide, alkanes  [192,266] 
Cystinuria  Human breath  Cadaverine, piperidine, putrescine, pyrrolidine  [42,267] 
Diabetes mellitus  Human breath  Acetone, ethanol, methyl nitrate, complex VOCs  [226,268] 
Eye infections  Cultures of ocular fluids  Specific complex mixture of VOCs  [176] 
Foetor hepaticus  Human breath  Specific complex mixture of VOCs  [269] 
Haematuria  Urine  Specific complex mixture of VOCs  [270] 
Halitosis  Human breath  Hydrogen sulfide, methyl mercaptan, dimethyl sulfide  [271] 
Hepatic cirrhosis  Alveolar breath  Dimethyl sulfide, hydrogen sulfide, mercaptans, volatile fatty acids [272] 
  Alveolar air  Dimethyl sulfide, acetone, 2-pentanone and 2-butanone  [273] 
 chronic  hepatitis  Methyl-mercaptan, dimethyl sulfide  [261,239] Sensors 2011, 11                                       
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Table 3. Cont. 
Disease/Disorder/Infection  Aroma sample source  Associated volatile biomarkers†  References 
Hepatic coma  Alveolar air  Methyl-mercaptan, dimethyl sulfide  [261,239,274] 
Hepatic encephalopathy  Blood plasma, spinal fluid  3-methylbutanal  [72] 
Histidinemia  Human breath  2-imidazolepyruvic acid, 2-imidazolelactic acid, 2-imidazoleacetic 
acid 
[42] 
Hyperglycemia  Human breath  Methyl nitrate, xylene, ethylbenzene  [183,268] 
Inflammatory bowel disease (IBD)  Human breath  Pentane, ethane, propane  [73,275-277] 
Isochemic heart disease, angina  Human breath  Alkanes, methylated alkanes  [278,279] 
Ketosis Alveolar  air  Acetone  [76] 
Leg ulcers & wound healing  Contact dressings  Specific complex mixture of VOCs  [280,281] 
Liver cancer  Blood  Hexanal, 1-octen-3-ol, octane  [282] 
Lung cancer  Human breath  Alkanes, monomethylated alkanes  [64,278] 
  Human breath  Alkanes, aromatic compounds  [283] 
  Human breath  Specific complex mixture of VOCs  [234,284-286] 
Maple syrup urine disease  Human breath  2-oxoisocaproic acid  [42] 
Metabolic disorders  Urine  Isovaleric acid  [287] 
Necrotizing enterocolitis (NEC)  Feces 2-Ethyl-1-hexanol,  fewer  esters present in VOCs  [288] 
Oxidative stress  Human breath  8-isoprostane  [247] 
Phenylketonuria Human  breath  Phenylpyruvic acid, phenyllactic acid, phenylacetic acid  [42] 
Renal dysfunction and failure  Urine  Specific complex mixture of VOCs  [270] 
Respiratory infections  Human breath  Specific complex mixture of VOCs  [289] 
Rheumatoid arthritis  Alveolar air  Pentane  [290] 
Tyrosinemia  Human breath  p-hydroxyphenylpyruvic acid  [42] 
Schizophrenia  Alveolar air  Pentane, carbon disulfide, ethane  [34,35,291] 
Sweaty feet syndrome  Urine, sweat, human breath  Butyric acid, hexanoic acid; trans-3-methyl-2 hexenoic acid  [37] 
Urinary tract infection  Urine  Isovaleric acid, alkanes  [245] 
  Urine  Specific complex mixture of VOCs  [245,292] 
† Bio-indicator compounds are volatile organic compounds (VOCs) that usually were initially identified and confirmed using gas chromatography-mass 
spectroscopy (GC-MS) or similar analytical equipment prior to development of corresponding e-nose reference libraries for detection. Sensors 2011, 11                                       
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Thorough investigations of e-nose detections of urinary trait infections have been done [258,270]. 
Aathithan et al. [258] conducted e-nose analysis of 534 clinical urine specimens of which 21% had 
significant bacteriuria indications. Electronic nose diagnoses were done at significantly lower costs 
and with greater sensitivity (83.5%) and specificity (87.5%) compared with conventional cultural 
counts. Pavlou et al. [296] proposed the use of the electronic nose as a potential diagnostic tool for 
patients afflicted with various kidney diseases. They were able to distinguish traces of blood in urine 
samples and obtain rapid identifications of E. coli, Proteus spp. and Staphylococcus spp. infections at 
very high levels of confidence. Lin et al. [297] developed an e-nose application for uremia diagnosis. 
Electronic-nose applications for diagnosis of diseases using samples taken externally from patients 
on body surfaces or from cultures of swabs taken from external orifices also have been developed. 
Boilot et al. [298] used a commercially-available electronic nose to classify six bacteria responsible for 
eye infections and ENT (ear, nose and throat) disease with an accuracy of 97.3% and 97.6% 
respectively. They effectively discriminated between pure laboratory cultures containing fixed 
volumes of bacteria in suspension and blood agar plates used to culture samples collected from 
diseased patients. Di Natale et al. [299] developed e-nose methods for the identification of diseases by 
odor analysis of VOCs from the human skin. 
Headspace analysis techniques have been developed to directly sample volatile metabolites 
produced by microbes in culture. These techniques involved sampling the culture headspace directly 
for aliphatic acids [11,300], amines [11], and sulfides of Proteus spp. [301], or via use of   
volatile-concentration methods [302-304]. Headspace analysis has been applied to samples of human 
body fluids including saliva [305], urine [306,307], and blood serum [308]. Anaerobic microbes 
generally are more limited in their production of volatile metabolic products compared to aerobic 
organisms that generate a wide variety of unique metabolites due to their ability to oxidize reduced 
substrates to various oxidation states [309-311]. Similarly, bacteria tend to produce a greater variety of 
oxidized volatile substrates than fungi which generally do not oxidize their substrates (as energy 
sources) to the same extent as indicated by large differences in e-nose sensory array outputs produced 
from headspace volatiles of these two groups of microbes [7]. 
Various odors and associated biomarker VOCs have been identified from cultures of a number of 
parasitic and pathogenic microbes, and in some cases, unique chemicals or chemical groups have been 
identified (Table 4). A wide diversity of different volatile secondary metabolites is produced as useful 
biomarkers even by different species within individual pathogenic bacterial genera. For example, 
pyrazines are produced by Pseudomonas taetrolens and Pseudomonas perolens [312,313],   
2-aminoacetophenone and dimethylsulfides by Pseudomonas putida and  Pseudomonas  
aeruginosa  [311,314], and isopentanol by Pseudomonas putrefaciens and Pseudomonas  
maltophilia [311]; esters, sulphur-containing compounds, and I-undecene by Pseudomonas species 
growing on beef products [315]. Similarly, Proteus species also produce a variety of different VOC 
biomarkers by various metabolic pathways. Biomarkers of Proteus species range from complex 
aldehydes and sulfides to a variety of sulfur-containing compounds (dimethyl sulphide, methyl 
mercaptan), trimethylamine, acetates, long-chain alcohols, and ketones [301,316,317]. Sensors 2011, 11                                       
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Table 4. Potential electronic-nose applications for human and animal disease diagnoses via detection of volatile biomarker indicator 
compounds produced by bacterial pathogens that are causal agents of specific diseases. 
Pathogenic agent  Disease  Aroma sample source Potential  biomarkers  References 
Campylobacter jejuni  Gastroenteritis Feces  Hexanal, (E)-2-octenal, pyrrole, ethyl 
ethanoate, methyl alcohol, 2-heptanone 
[74] 
Clostridium septicum  Intestinal disease  Culture from intestine  Isobutylamine, isopentylamine, ethylamine [11] 
Enterococcus faecalis  Gastroesophageal disease  Complex broth cultures  Terpenes, trimethylamine, ketones  [244] 
Escherichia coli  Gastrointestinal diseases  Complex broth cultures  Terpenes, trimethylamine, ketones; ethanol [244,320] 
Helicobacter pylori  Stomach ulcers  Gastroesophageal cultures  Terpenes, trimethylamine, ketones  [244] 
Klebsiella pneumoniae Gastrointestinal  diseases  Urine  Trimethylamine, ethyl acetate  [9] 
Mycobacterium tuberculosis  Tuberculosis  Human sputum cultures  Specific complex mixture of VOCs  [17,27,302,321] 
Proteus mirabilis  Urinary tract infections  Urine  Benzaldehyde, isobutyraldehyde, 
isovalaraldehyde; sulfides 
[301,316] 
  Urinary tract infections  Urine  Dimethyl sulphide, methyl mercaptan  [301] 
  Urinary tract infections  Urine  Trimethylamine, ethyl acetate  [9] 
  Urinary tract infections  Urine  Isobutanol, isopentyl acetate ketones,  
I-undecene 
[287,317] 
Pseudomonas aeuroginosa  Localized infections  Skin, lung  Butanol, methyl ketones 




Pseudomonas perolens, P. 
taetrolens 
Food poisoning (eggs etc.) Stomach  2-methoxy-3-isopropylpyrazine 
(MIPP) 
[312,313] 
Staphalococcus aureus  Localized & systemic infections  All parts of the body  Isobutanol, isopentyl acetate 
ketones, I-undecene 
[318] 
Vibrio cholerae  Cholera Feces  p-menth-1-en-8-ol,  dimethyl 
disulphide  [74] 
† Bio-indicator compounds are volatile organic compounds (VOCs) that usually were initially identified and confirmed using gas chromatography-mass 
spectroscopy (GC-MS) or similar analytical equipment prior to development of corresponding e-nose reference libraries for detection. Sensors 2011, 11                                       
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The production of the same identical biomarker VOCs can be indicative of several different 
diseases cause by totally different bacterial species. Certain gastrointestinal and gastroesophageal 
diseases caused by Enterococcus species, Escherichia coli, and Helicobacter pylori are all known to 
produce terpenes, trimethylamine, and ketone bioindicator compounds [244]. Vibrio cholerae that 
causes cholera and Proteus species that cause gastroenteritis are both producers of the bioindicator 
dimethyl disulphide. The bioindicator compound I-undecene is produced in common by 
Staphalococcus aureus that causes staph infections and Proteus mirabilis that causes the majority of 
Proteus infections associated with gastrointestinal diseases [288,317,318]. 
Recently, the use of aroma analysis in clinical diagnosis has been rediscovered due to major 
advances in odor-sensing technology and artificial intelligence. The use of VOC biomarkers in disease 
diagnosis will likely become increasingly important in the future as more information becomes 
available on new biomarker indicator compounds associated with specific diseases, and as biomarker 
detection with electronic noses becomes routine in clinical practice. Increasing worldwide awareness 
that bionics and artificial intelligence will play an important role in microbial analysis has prompted 
the development of intelligent data-warehouse systems consisting of odor-generation mechanisms for 
rapid aroma volatile delivery and recovery (from human samples) coupled with classifier systems 
based on neural networks and genetic algorithms [318,319]. Microbiological warehouse environment 
systems adopt the concept of fusion of multiple classifiers dedicated to specific feature parameters or 
applications. Such data-warehouse systems should ultimately produce a worldwide database that can 
be accessed and utilized by researchers and developers of medical aroma-based disease-diagnostic 
instruments, such as electronic noses, to generate reference libraries that may be used to detect VOC 
biomarkers for the identification of specific diseases. In this way, application-specific e-nose systems 
with limited recognition libraries may be developed for a fairly narrow range of diseases to limit 
instrument costs and increase portability through reducing the number of sensors (in the sensor array) 
to the minimum needed for effective discriminations [7,8]. 
4.2. E-Nose Detection of Nosocomial Diseases 
Nosocomial infections are microbial infections that result from treatment in a hospital or a 
healthcare service unit. Infections are considered nosocomial if they first appear 48 hours or more after 
hospital admission or within 30 days after discharge. This type of infection is also known as   
hospital-acquired infection or healthcare-associated infection. The Centers for Disease Control (CDC) 
estimate that roughly 1.7 million hospital-associated bacterial infections of all types cause or 
contribute to 99,000 deaths annually [322]. Nosocomial infections are commonly transmitted when 
hospital officials become complacent or personnel do not practice correct hygiene consistently [323]. 
The increased use of outpatient treatments has resulted in hospital patients that generally are more ill 
and have more weakened immune systems than in the past. 
Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) 
are two hospital-linked staph strains that can cause mild to severe infections of bones, lungs, heart and 
blood stream. Some species of Staphylococcus, such as S. epidermis and S. saprophyticus, are known 
as coagulase-negative staphylococci (C-NS) that are among the most commonly isolated bacteria in 
clinical microbiology laboratories and can cause infections to immunocompromised patients.   Sensors 2011, 11                                       
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Lai et al. [232] analyzed swabs of Staphylococcus aureus, Streptococcus pneumonia, Haemophylus 
influenza and Pseudomonas aeruginosa, all common upper respiratory bacterial pathogens, using the 
Cyranose 320 e-nose. Discrimination between the sample types was performed using pairwise 
comparisons with Mahlanobis distance (MD). The electronic nose could easily distinguish between the 
four bacterial species and controls as indicated by MD values of 3 or greater for pairwise comparisons 
in all possible combinations. 
A relatively small group of microbial pathogens are opportunistic generalists that possess 
pathogenic determinants (i.e., chemical or genetic components that are responsible for disease-causing 
mechanisms) that enable them with the capability of causing disease in a wider group of unrelated 
multicellular organisms. Pathogenic determinants produced by virulent bacteria can be such things as 
toxins, destructive enzyme and protein systems, polysaccharide slime, and plasmids that are the actual 
integral molecular machinery actively involved in causing or generating the disease process 
(pathogenesis) and immune responses. As a consequence, these pathogenic microbes are capable of 
causing diseases in both plants and animals, particularly humans in debilitated states such as patients 
receiving treatment or recovering from illnesses in the hospital setting. Nosocomial diseases can occur 
as a result of infection of patients by phytopathogenic microbes derived from infected plants. The 
capability of certain plant pathogenic microbes to “jump” from infected plants or plant materials to 
debilitated human subjects has long been known as one of the potential exposure hazards prevalent in 
the hospital environment. Compromised patients can become exposed to these microorganisms 
through infected plants, particularly flowering plants that are brought into the hospital and given as 
gifts to patients. The giving of plants or plant materials has since been strongly discouraged or 
forbidden in many modern hospitals to minimize the risks of nosocomial secondary infections that can 
potentially complicate or prolong the patient-recovery phase associated with the original illness. The 
strongly opportunistic capabilities of these select microbes to cause pathogenesis in unrelated higher 
organisms has been an area of fascination and a subject of research that particularly lends well to  
e-nose applications due to the commonality of mechanisms responsible for disease development in all 
multicellular hosts, whether plants, animals, or humans. A list of these opportunistic nosocomial 
microbes, capable of infecting both plants and humans, that potentially could be detected using e-nose 
technologies are presented in Table 5. Although this list is not comprehensive, it represents some of 
the more common microbial pathogens present in the hospital environment, particularly prevalent on 
plant surfaces or as airborne spores that are brought into the vicinity of susceptible human subjects. 
Nosocomial diseases of humans, caused by opportunistic bacterial and fungal plant pathogens, are 
possible largely due to the existence of common virulence factors for pathogenicity and disease 
mechanisms that operate equally well against both plant and human hosts [372]. These microbes take 
advantage of accidental or incidental entries into the human body that often occur due to skin contact 
with plant parts. For example, Pantoea agglomerans-infections usually occur following tramal skin 
penetration by vegetative thorns, spines, or prickles that have surfaces contaminated with a resident 
population of this pathogen [330]. Three other bacterial genera (Burkholderia,  Pseudomonas and 
Ralstonia) that frequent surfaces of plant roots and foliage also are capable of causing opportunistic 
infections in vulnerable individuals, particularly patients with cystic fibrosis (CF) [336]. Thus, these 
bacteria also are opportunistic in taking advantage of underlying physiological conditions, Sensors 2011, 11                                       
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compromised immunities, and debilitating diseases, creating significant problems in clinical settings 
due to their widespread cause of nosocomial infections. 
Table 5. Nosocomial opportunistic pathogens detectable with e-nose instruments as 
disease-causing agents of both plants and humans in the hospital environment. 
Pathogenic microbe  Plant diseases Human  diseases  References 
Bacterial pathogens      
Burkholderia cenocepacia  Banana finger-tip rot  Increases mortality in cystic 
fibrosis patients 
[324-326] 
Burkholderia cepacia  Onion soft rot 
(sour skin) 
Pulmonary infections particularly 
in cystic fibrosis patients, 
pneumonia, septicemia 
[325,327,328] 
Burkholderia dolosa Opportunist  plant 
 pathogen 
Increases mortality in cystic 
fibrosis patients 
[325,326] 
Pantoea agglomerans  Epidermal surfaces of 
thorny plants 
Soft tissue and bone/joint infections  
 
[329-332] 
Ralstonia syzygii  Clove tree, banana  Blood-borne diseases  [333,334] 
Ralstonia taiwanensis  Root nodules of 
Mimosa spp. 
Opportunistic infections of 
cystic fibrosis patients 
[335] 
Pseudomonas aeruginosa  Many plants spp.  Pneumonia, urinary tract 
infections, respiratory infections, 





Plant endophyte  pneumonia, urinary tract and 
 blood stream infections 
[338,339] 
      
Fungal pathogens      
Acremonium falciforme  Saprophyte on 
plant debris 
Cutaneous and subcutaneous 
mycetomas 
[340,341] 
Aspergillus flavus  Rots maize, peanuts  chronic sinusitis, keratitis, 
cutaneous aspergillosis,  
wound infections, osteomyelitis, 
aflatoxin toxicosis 
[342] 
Aspergillus nidulans  Bean, pea, and 
cucumber leaf 
 spots, orange rot 
Cutaneous and subcutaneous 
mycetomas 
[343,344] 
Cercospora apii  Celery, beet, tomato, 
lettuce, tobacco, 
potato leaf spots 






Plant leaf spots  Chromomycosis skin infections  [347-350] 
 
Coccidioides immitis    Respiratory tract, skin, bones, 
central nervous system infections 
[351] 
 
Fonsecaea pedrosoi    Chromomycosis skin infections  [347,352] 
Fusarium graminearum  Wheat, barley, rice, 
head blight 
Alimentary toxic aleukia, weight 
loss, convulsions, anorexia, 
impaired immunity 
[353-355] Sensors 2011, 11                                       
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Table 5. Cont. 
Pathogenic microbe  Plant diseases  Human diseases  References 
Fusarium moniliforme  Vegetable seed rot  Fusarium sepsis  [356,357] 
Fusarium oxysporum  Vascular wilt of 




Fusarium solani, roseum  Vascular wilt of 
solanaceous plants 
Skin lesions, encephalopathy, 
panophthalmitis, keratitis 
[360,361] 
Geotrichum candidum  Fruit & vegetable 
saprophyte 
Oral, vaginal, skin, & systemic 
infections 
[362-364] 
Geotrichum capitatum  Surfaces of plant 
foods (ingested) 
Septicemia, meningitis, discitis, 
encephalitis, endocarditis, vertebral 
osteomyelitis, , respiratory tract & 
gastrointestinal infections 
[365] 
Phialophora verrucosa  Wood and woody 
plant surfaces 
Chromomycosis, cutaneous and 
subcutaneous infections 
[347,366,367] 
Pseudallescheria boydii  Saprophyte of  
vegetable oils 
and tissues  
Cutaneous and subcutaneous 
mycetomas, systemic infections 
[368-371] 
 
The Burkholderia cepacia complex (BCC) is a group of bacteria that comprises at least nine distinct 
Burkholderia species [325]. The type species was originally identified as a plant pathogen by   
W. H. Burkholder in 1950, when it was identified as the causative agent of onion soft rot disease called 
sour skin [327]. BCC bacteria are ubiquitous in the environment and important opportunistic 
pathogens that cause lung infections in CF patients, resulting in asymptomatic carriage, chronic 
infection or ‘cepacia syndrome’, characterized by rapid decline in lung function. Like other 
opportunistic pathogens such as Pseudomonas aeruginosa, BCC strains do not normally infect healthy 
individuals, but only those whose immune systems are compromised [373]. CF patients are 
particularly susceptible to BCC lung infections that have a significant impact on morbidity and 
mortality [373,374]. BCC bacteria are frequently cultured in the blood due to the systemic nature of 
the infections that often lead to sepsis and pneumonia, the second most common cause of death in 
Chronic Granulomatous Disease (CGD) patients [375,376]. Within the past 20 years, BCC bacteria 
have emerged as highly problematic human pathogens in CF and immunocompromised individuals, 
and the incidence of BCC infections have increased in these patient groups [377,378]. This increase 
may be due to increasing numbers of immunocompromised patients, increased population age of these 
patients [379], more accurate identification of BCC microbes [380,381], social and behavioral changes 
allowing close contact between patients [382], and increased use of antibiotics to which BCC bacteria 
are resistant [383]. 
Many bacterial plant pathogens in the genus Pseudomonas have long been known to cause human 
diseases. Patients who are in intensive care units for extended periods of time are most at risk for 
contracting a disease caused by a P. aeruginosa infection, especially burn victims and those with cancer 
or cystic fibrosis. The major nosocomial pathogens that attack debilitated patients in intensive care units 
include  Pseudomonas aeruginosa,  Acinetobacter baumannii,  Stenotrophomonas maltophilia and 
Burkholderia cepacia. Pseudomonas cepacia was transferred to a new genus, Burkholderia in 1992 [384]. Sensors 2011, 11                                       
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Ralstonia is a relatively new genus that includes former members of Burkholderia  spp. 
(Burkholderia pickettii and Burkholderia solanacearum) commonly found in water and soil in the 
environment. Ralstonia pickettii has been isolated from a wide variety of clinical specimens including 
blood, urine and cerebrospinal fluid [385]. Although Ralstonia pickettii is regarded to be of minor 
clinical significance due to its low virulence, a wide range of invasive and severe infections have been 
reported indicating that this microbe may be a more widespread and serious pathogen than previously 
thought [386]. Infections include bacteremia and septicemia caused by contaminated solutions, e.g., 
distilled water, water for injection and aqueous chlorhexidine solutions [386]. It also has been 
identified in ultrapure water systems of industry [387], the space shuttle [388], and laboratories [389]. 
Cases of pseudobacteremia and unusual infections have been associated with R. pickettii with some 
being very invasive and severe such as meningitis, septic arthritis and osteomyelitis that have resulted 
in a significant number of clinical deaths [386]. 
Acinetobacter baumannii is an important pathogen that is increasingly recognized as the cause of 
severe infections in compromised hospitalized patients [390,391]. Deadly cases of   
community-acquired pneumonia have been reported among immune-compromised patients [392,393]. 
These infections are difficult to treat due to the expanding antibiotic resistance of clinical   
strains [394,395]. Acinetobacter baumannii is a metabolically versatile pathogen, yet little is known 
about the genes and factors involved in its basic physiology and virulence properties. Some evidence 
indicates that the ability of A. baumannii to produce and secrete certain proteins for biofilm production 
may be involved in pathogenesis [396]. 
Detection of nosocomial bacteria and diseases using electronic noses can be achieved with the same 
methods utilized for their detection as microbial plant pathogens, even though not all nosocomial 
pathogens are plant pathogens. Wilson et al. [7,122] pioneered the application of the electronic nose 
for the detection and identification of plant pathogenic (phytopathogenic) microbes, including bacterial 
and fungal plant pathogens, the diseases they cause in multicellular higher plants [7,122,397], wood 
decay fungi and incipient wood decay [7,398], and the identification of plants and woody plant hosts 
by the unique Electronic Aroma Signature Patterns (EASPs) produced by various e-nose sensor arrays 
in response to headspace volatiles [399]. These e-nose applications for the field of plant pathology 
developed out of the realization that all pathogenic microbial species produce a very specific 
combination or mixture of volatile metabolites that are products of various specialized metabolic (both 
anabolic and catabolic) pathways involved in biosynthesis and the production of energy for cellular 
activities. The typical sensor array in an electronic nose can detect and distinguish between different 
specific mixtures of volatile metabolites, produced by different microbial pathogens, as unique 
electronic digital fingerprints that identify a specific volatile mixture as being produced only by one 
particular microbial species. The diagnostic recognition of these very specific mixtures of volatiles of 
particular microbes is possible by using application-specific reference libraries (recognition files), 
created from samples of known pathogenic microbes, allowing the identification of the causal agent(s) 
of unknown diseases based on VOC headspace volatiles released from diseased tissues. The   
response-specificity of the sensory output from a sensor array is so large that differences in response 
patterns are produced from mixtures containing exactly the same components (chemical species) when 
only the molar ratio of components in the mixture is changed [7]. Thus, differences in EASPs result 
even when there are changes in the relative amounts of VOCs present in headspace volatiles. This is Sensors 2011, 11                                       
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important because many microbes utilize many of the same metabolic pathways, but generate different 
ratios of metabolic products due to slight changes or substitutions in the sequences of chemical 
reactions that occur within a metabolic pathway or to different proportions of different pathways 
utilized in their metabolism. The result of different molar ratios of metabolites, generated by variable 
metabolic pathways in operation in different microbial strains, is accounted for by different 
proportions of metabolic products produced as a result of unique pathway usage that is governed by  
gene-regulation (genetic) processes. 
Nosocomial mycoses caused by Fusarium species are particularly common secondary infections 
associated with debilitated patients in the hospital setting. Fusaria are facultative fungal saprophytes 
that survive on overwintering plant debris, remaining after the harvesting of field crops, or as resistant 
spores (chlamydospores) in the soils of agricultural fields. For example, these saprobic fungi are 
commonly found on overwintering cereal crops [400]. The spores of these fungi become airborne from 
soil particles or plant surfaces when fields are cultivated in the spring or crops are harvested at the end 
of the season. Air-borne spores gain access to the hospital environment primarily through hospital air 
exchanges with the outside via air entry/exit points. Inoculum is dispersed through air vents. Fusarium 
species often cause sapronosis-type diseases that are defined generally as diseases caused by saprobes 
in patients or subjects with impaired resistance [401]. Fusarium skin infections often have been 
associated with burned human tissues [402,403], facial granulomas [404], skin lesions [360,361], and 
eye infections or keratosis [405,406]. Once Fusarium inoculum is in the body, it can disseminate to 
other areas of the body through the circulatory system and infect internal organs [358,407-409]. 
Infections due to Fusarium species also have been associated with patients having osteomyelitis [410], 
catheter-associated fungemia in lymphocytic lymphoma patients [409], myasthenic syndrome 
associated with aplastic anemia [407], and renal and bone marrow transplants [411,412]. 
Electronic noses may be used to detect either Fusarium-specific VOC metabolites or toxins, 
produced by the somatic hyphae of these fungi in plant residues, or released in isolated pure cultures of 
these fungi [7]. The detection of Fusarium mycoses in human burn wounds and infected organs is 
made possible by the identification of abnormal fungal metabolites released into infected human 
tissues. The careful selection of sensor types (within the sensor array of the e-nose) which are sensitive 
to the specific chemical groups of metabolic VOCs produced by Fusarium species within affected 
tissues, provides optimal means for detection of Fusarium infections and allows for a high level of 
selectivity required of application-specific detection methods. This approach assures that e-nose 
detections are both cheap and effective for real-time diagnoses. Aroma recognition libraries utilized 
with pattern-recognition algorithms, developed specifically for Fusarium VOC metabolites or toxins, 
would provide the greatest specificity of detection. Fusarium species produce a wide range of 
important toxins in plant residues, some of which are carcinogens, such as beauvericin [413], 
fumonisins, [414,415], trichothecenes [416], as well as deoxynivalenol, T-2 toxin, HT-2 toxin, and T-2 
tetraol [417]. Fusarium-specific toxins may serve as effective targets for e-nose detection if similar 
toxic analogs are constitutively produced in human tissues. Sensors 2011, 11                                       
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5. Electronic-Nose Instruments Used for Biomedical Applications 
Electronic-nose applications developed for the biomedical field are growing at a rapid rate due to 
increasing demand for simple and effective solutions to the numerous problems and diagnostic needs 
of modern medicine. The strong inclination of private industrial biotechnology firms to shift their 
research and development (R&D) departments toward development of e-nose technologies for the 
medical industry is related to the higher cost of detection-instruments needed for disease diagnoses, 
increasing demand for specialized detection instruments at large numbers of medical and research 
facilities, the greater availability of funding for instrument purchases, and the increased visibility of 
biomedical needs [8]. The shift in R&D activities of commercial companies to development of 
electronic noses also has occurred in response to social, economic, and profit-motivated factors. Some 
instrument-development companies have shifted their entire R&D programs toward e-nose biomedical 
applications. Electronic-nose instruments developed for diagnostic medical applications often are more 
specialized, higher priced, and more lucrative for commercial development. With numerous diverse 
and specialized applications possible, there are many motivations for e-nose producers to focus their 
R&D efforts in the field of diagnostic medical-instrumentation development.  
A wide diversity of biomedical applications has been developed from commercially-available 
electronic noses since 1998 (Table 6). These applications are many and varied and range from specific 
diagnostic detections of microbes, hazardous chemicals, toxins and various types of infection, to drug 
formulation and development. The number of sensors used in the arrays of these e-noses varies widely. 
The development of various biomedical applications using electronic-nose technologies has 
involved more than a dozen different commercially-available e-nose instruments. Hitherto, the vast 
majority of e-nose instruments employed for medical applications, including Amperometric Gas 
Sensors (AGS), Conducting Polymers (CP), Metal-Oxide Semiconductors (MOS), Quartz 
Microbalance (QMB), and Surface Acoustic Wave (SAW) sensors, represent a relatively small number 
of e-nose technology types that are available. Most biomedical e-nose applications have involved the 
use of MOS sensor arrays containing a variable number of sensors. The utilization of MOS sensors is 
somewhat surprising given that metal-oxide semiconductor sensors generally must operate at high 
temperatures and require high power consumption for detection. These requirements increase 
operating costs and greatly limit portability that is required for mobile medical services. MOS sensors 
also have limited VOC-sensing range with the capability of detecting only low molecular weight 
compounds. Furthermore, MOS sensors are sensitive to humidity, susceptible to sulfur and weak acid 
poisoning, and have limited sensor coatings [8]. By contrast, sensor arrays consisting of CP, QMB, 
SAW and optical sensors are probably better suited for most biomedical applications due to the 
capabilities of detecting a very wide range of VOCs (in terms of both chemical-class diversity and 
molecular-weight range) and the more preferred characteristics of high sensitivity and precision, good 
response and recovery times, small portable sizes, and relatively low purchase and operating costs. 
Many types of biosensors also are being developed for medical applications and will likely provide 
another very fruitful area for diagnostic methods development. Sensors 2011, 11                                       
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Table 6. Biomedical applications developed using commercial and experimental electronic noses. 
E-nose model  Manufacturer  Sensors† Biomedical application  References 
Bloodhound BH-114  Sensors Ltd.  14 CP 
Detect bacteria and heavy 
metals in potable water 
[172,418] 
      Early detection of TB  [321,196] 
 
  
Detect spoilage bacteria and 
fungi in food 
[419-422] 






      Urinary tract infections  [245] 
 
  
Early disease diagnosis, 
distinguish dermatophytes 
[423] 
Cyranose C320  Cyrano Sciences  32 CP  Bacterial & SA infections  [123,176] 
      Pneumonia score prediction  [231] 
 
  
Upper respiratory tract 
infections 
[232] 
      Lung cancer detection  [234] 
      Ear, nose, throat infections  [233] 
 
  
Bacteria identifications in 
blood and urine samples 
[424] 
DE 101  Experimental 
model 
3 MOS  Detect renal dysfunction  [191] 
EOS 835  Sacmi Imola  6 MOS  Toxigenic Fusarium in corn  [160] 
FF-1 Experimental 
model 
6 MOS  Oral malodor assessment   [425] 
Fox 2000  Alpha MOS  6 MOS  Culture growth phases  [124] 
     Diagnose  diseases  [103] 
Fox 4000 
Alpha MOS  18 MOS 
Flavor analysis to develop 
new drug formulations 
[136] 
JPL ENose  NASA  16 CP  Brain cancer detection  [193] 
KAMINA Karlsruhe  Res. 
Cntr. 
38 MOS 
Ammonia and chloroform 
hazard-detection 
[426] 




8 MOS,  
8 QMB,  
4 AGS 
Discriminate coliform bacteria  [218] 
PEN 2  Airsense 
Analytical 
10 MOS 
Clinical diagnoses, Identify 
bacteria 
[427] 
      Aflatoxin detection in corn  [162,216] 
ZNose   Electronic Sensor 
Technology 
1 SAW  Identify bacteria & yeasts  [428] 
† Sensor type abbreviations: Amperometric Gas Sensors (AGS); Conducting Polymers (CP); Metal-Oxide 
Semiconductors (MOS); Quartz Microbalance (QMB); Surface Acoustic Wave (SAW). The numerical values 
before each sensor type indicate the number of each sensor type present within the instrument sensor array. 




Great progress has been achieved in the use of e-nose devices to diagnose and monitor diabetes in 
clinical patients. Ping et al. [226] developed a self-made MOS e-nose for the diagnosis of diabetes. 
Their analyses were performed by a prototype with thin-film sensors coated with SnO2, having high 
selectivity for acetone, the most important chemical marker detected in the exhaled breath of diabetic 
patients. In a more recent study, Guo et al. [429] classified subjects with renal failure before and after 
hemodialysis using breath samples captured and analyzed with an electronic-nose gas sensor. They 
successfully applied a similar MOS e-nose prototype system to distinguish between 14 healthy and 18 
diabetic subjects suffering from diabetes, renal disease and airway inflammation based on analyses of 
breath odor. Cluster analysis indicated that diabetic and non-diabetic subjects sampled before a meal 
were diagnosed correctly, whereas some controls were mistaken for diabetics due to the rise in acetone 
concentration associated with hunger. One hour after a meal, 100% of diabetics were discriminated 
from non-diabetics using the e-nose breath tests. 
5.2. Nasal Infections 
Subjects affected by chronic nasal or paranasal infections often are characterized by peculiar odors 
in their nasal out-breaths that are usually associated with bacterial or fungal colonization of the sinuses. 
A first study aimed at examining nasal out-breath samples from patients with chronic rhinosinusitis 
(CRS) was done using an electronic nose developed by Mohamed et al. [430] in 2003. This e-nose 
correctly classified diseased and healthy controls in 80% of the samples. They employed ANN 
analysis to correctly classified 60% of the VOC patterns of both groups. In a follow-up study 
conducted by the same research group, Bruno et al. [431] employed a new and more sophisticated 
electronic nose (ZNose
TM) based on both gas-chromatography and Surface Acoustic Wave (SAW) 
sensor technology capable of detecting pictograms of VOCs in less than 10 seconds. In pathologic 
subjects, six odorous components ranging from C6 to C14 were found useful in the diagnosis of 
chronic rhinosinusitis. 
5.3. Urogenital Infections 
The diagnostic criteria of urogenital infections are based on macroscopic and microscopic 
characteristics of urine together with chemical and/or physical analyses of the blood or urogenital 
discharges. In particular, the diagnosis of bacterial vaginosis, one of the most common causes of 
vaginal infection, is performed by the appearance and pH of vaginal discharge and the emission of 
amine odor after the addition of KOH. Chandiok et al. [121], conducted a study to test the feasibility 
of an electronic nose to diagnose bacterial vaginosis with urine samples taken from 68 women. They 
found 94% of known positive cases were recognized as positive by the e-nose using a trained ANN. 
Approximately 43% were negative based on clinical criteria and 33% were recognized as negative  
and 23.3% as positive by the e-nose. The positive predictive value for the combined test (e-nose plus 
clinical assessment) was 61%. 
The presence of blood and VOCs in urine samples of children affected by kidney diseases was 
studied by Di Natale et al. [270] in 1999. A Quartz Microbalance (QMB) electronic nose prototype Sensors 2011, 11                                       
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was used to evaluate the pH and specific weight of urine samples. The presence of microorganisms in 
a large number of human urine samples was analyzed by Aathithan et al. [258] in 2001 using an  
e-nose. They employed the Osmetech Microbial Analyzer, a headspace analyzer with an array of four 
Conducting Polymer (CP) gas sensors, to detect bacteriuria in 534 clinical urine specimens. The results 
showed an accuracy of 72% and a specificity of 90% in samples with a microbial concentration of 
≥10
4 colony forming units (CFU) per milliliter, and an accuracy of 83% and a specificity of 88% when 
the microbial concentration was ≥10
5 CFU/mL. 
Kodogiannis et al. [292,432] employed the Bloodhound BH-114 e-nose, based on 14 CP gas 
sensors, for the early diagnosis of infections in the urinary tract of 45 suspected cases. The study 
demonstrated that this e-nose, combined with advanced learning-based processing tools, was able to 
identify specific bacterial pathogens with high speed and accuracy. Witt et al. [433] used an e-nose 
with CPA and a quadratic discriminant algorithm to analyze the skin volatiles at the skin surface of 
patients with liver cirrhosis and addiction to alcohol. They found sweat volatile gases are changed 
because of the liver dysfunction and remaining alcoholics and alcoholic decomposition products 
within the blood. These diseases lead to changes in metabolic balance. They developed a special 
applicator to collect and analyze the transpired dermal gases directly on the skin surface. They showed 
in a pilot study on 25 patients that an electronic nose is able to detect changes in the human body odor 
and to discriminate between healthy subjects (controls), patients with liver cirrhosis and patients 
addicted to alcohol. 
6. Biomedical Research Developments for Electronic Noses 
Electronic-nose systems have been designed specifically to be used for numerous applications in 
many different biomedical applications. The development of e-nose diagnostic detection methods 
using commercially-available e-nose instruments has a sound foundation with numerous examples of 
proven and documented successful applications. However, many new interesting and useful e-nose 
applications currently are under development and forthcoming in extant research efforts. For example, 
many important recent studies have been investigating the sensorial analysis of human breath to 
potentially provide rapid and dependable diagnoses of many human diseases based on the detection of 
bioindicator compounds and specific mixtures of aberrant VOCs in human breath samples. Some 
examples of these new research developments and discoveries of new e-nose theoretical applications 
are provided in the following discussion. 
6.1. Asthma and Respiratory-Disease Detection 
The investigation of human breath samples with conventional analytical methods has shown a 
correlation between specific VOCs or VOC mixtures and the occurrence of certain illnesses. Asthma, 
one of the most important lung diseases in clinical practice, currently is diagnosed and monitored by 
symptoms and physiological measurements. These tests have been internationally standardized and are 
considered to be reliable, but rather complex, time-consuming and not widely applicable in many cases. 
During the past decade, new options for diagnosis and monitoring lung diseases like asthma have been 
proposed. These include the determination of nitric oxide in exhaled air which appears to have a 
realistic potential of widespread application due to its simplicity [434,435]. It is also well recognized Sensors 2011, 11                                       
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that the exhaled breath is composed by thousands of VOCs of which nitric oxide is only one of these. 
Thus, measurement of nitric oxide alone is not always sufficient to determine the identity or severity of 
a disease. For these reasons, Dragonieri et al. [250] in 2007 postulated the possibility of testing the 
capability of an electronic nose to discriminate exhaled breath of patients with asthma from healthy 
controls and to distinguish between different levels of asthma severity. The study was based on 40 
nonsmoking adults subjects, divided into four groups based on a standard sample size (10 patients with 
mild asthma, 10 with intermittent-mild asthma, 10 with moderate-severe persistent asthma, and 10 in 
the healthy control group). The exhaled breath samples were analyzed by the Cyranose 320   
e-nose. The result showed that this electronic nose could successfully discriminate between patients 
with mild asthma and moderately-severe asthma compared with controls, but it could not adequately 
discriminate between mild and severe asthma samples, indicated by an M-distance of only 1.23 
between these two groups.  
A recent study by Montuschi et al. [436] tested whether differences between alveolar and 
oropharyngeal/airway air could affect e-nose results when analyzing VOCs in exhaled breath. The 
study tried to ascertain whether an electronic nose could discriminate between patients with asthma 
and healthy subjects and to determine the best sampling protocol (alveolar vs oropharyngeal/airway 
air). They also compared the discrimination performance of the same electronic nose based on 
fractional exhaled iron nitric oxide (FeNO) in patients with moderately severe asthma. An 
experimental prototype electronic nose, containing eight QMV sensors coated with molecular films of 
metalloporphyrins designed at the University of Tor Vergata, gave the best results when performed on 
alveolar air. Moreover, the combination of electronic nose analysis of alveolar air and FeNO had the 
highest diagnostic performance for asthma (95.8%). Electronic nose analysis of alveolar air effectively 
discriminated between patients with asthma and healthy subjects in 87.5% of cases, much higher than 
for FeNO (79.2%), spirometry (70.8%), and a combination of FeNO and spirometry (83.3%).  
Fens et al. [285] tested the possibility of using the electronic nose to discriminate between two 
diseases, Chronic Obstructive Pulmonary Disease (COPD) and asthma, which often exhibit 
overlapping clinical characteristics. The test groups consisted of 30 patients with COPD, 20 patients 
with asthma, 20 nonsmoking control subjects, and 20 smoking control subjects who participated in the 
study. Breath prints from patients with asthma were statistically well separated from patients with 
COPD at high levels of confidence (accuracy 96%, P < 0.001). Asthma patients also were statistically 
different from nonsmoking controls (95%) and from smoking control subjects (92.5%). Exhaled breath 
profiles of patients with COPD partially overlapped with those of smoking control subjects (accuracy 
66%; P = 0.006). 
The World Health Organization (WHO) has declared tuberculosis, a deadly infectious lung disease 
caused by the bacterium Mycobacterium tuberculosis (TB) that may attack other parts of the body, a 
global emergency. An estimated one-third of the world’s population is infected by the microbe. The 
majority of new infections take place in developing countries. The usual diagnostic method for TB 
involves the detection of acid-fast bacteria in the sputum by direct microscopy or by the Ziehl-Neelsen 
staining procedure which is often difficult. Pavlou et al. [196] investigated the possibility of detecting 
Mycobacterium species in vitro and in situ in sputum samples of TB-positive and TB-negative subjects. 
In this earlier study, the electronic nose successfully discriminated the TB-positive samples from the 
negative controls and between the different Mycobacterium  species. In 2006, Fend et al. [321] Sensors 2011, 11                                       
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investigated the potential of an electronic nose to detect the presence of Mycobacterium species in 
pure cultures and sputum samples from 280 patients with suspected TB and 50 non-TB controls in 
order to find a new fast and inexpensive TB-diagnostic method. A 14 CP-based electronic nose 
provided encouraging results. All unknown samples were correctly classified and the three different 
Mycobacterium species tested were closely clustered, but still effectively discriminated by   
statistical analysis.  
Pneumonia is an inflammatory condition of the lungs caused by infections of bacteria, virus, fungi 
or other parasites, and by chemical or physical injury to the lungs. To date, there is no gold standard in 
the diagnosis of pneumonia. Diagnosis is based on a combination of all available data resulting from 
chest radiography, bronchoscopy, chest-computed tomography, and microscopic examination of the 
sputum. Hockstein et al. [229,230] proposed a novel method to diagnose pneumonia in patients 
receiving mechanical ventilation by means of the Cyranose 320 electronic nose. In both studies, this  
e-nose correctly discriminated between pneumonia-positive and pneumonia-negative patients. Good 
results also were obtained by Hanson and Thaler [231] based on e-nose analysis of 38 randomly 
selected mechanically-ventilated samples from 400 patients. 
6.2. Biochemical Assays and Physiological Lab Tests 
The application of electronic noses in biochemical and physiological assays for determining patient 
conditions and physiological states has been tested in several studies. Chen et al. [126] utilized 
magnetron sputtering and thermal oxidation titanium oxide thin films to determine blood compatibility 
in antithrombogenic investigations. Improvements in antithrombogenic properties of blood contacting 
biomaterials permitted a hybrid design of layers for biomedical applications such as artificial heart 
valves and stents. Xu et al. [125] developed a way to highly integrate different analytical operations 
such as sample preparation, separation, and detection into a single miniaturized device with the 
advantages of low cost, satisfactory analytical efficiency and flexibility in design. This integration of 
electrochemistry in microdevices for biochemical assays focused on in situ analysis, point-of-care 
testing and portable devices with simplicity, rapidity, high sensitivity, reduced power consumption, 
and sample/reagent economy. Easy microfabrication and integration of electrochemical components 
with multi-analytical functions was achieved at low cost. Such integrated microsystems likely will 
play an increasingly important role for analysis of small-volume biochemical tests.  
6.3. Microbial Identifications in Culture and Body Fluids 
Pavlou et al. [244] discriminated between headspace volatiles from complex broth cultures of some 
highly pathogenic gastroesophageal bacteria including Staphylococcus aureus,  Klebsiella spp., 
Helicobacter pylori (the most common ulcer-causing pathogen) and Enterococcus faecalis. These 
bacteria were successfully identified at a diluted concentration of 10
7 CFU mL
−1. Other in vitro studies 
have involved recognition of several strains of two anaerobic bacteria (14 strains of Clostridium spp. 
and 12 strains of Bacteroides fragilis) and two fecal pathogens (E. coli and Salmonella typhimurium) 
by the use of an electronic nose [296,437]. Moens et al. [438] were able to identify ten clinically 
important microorganisms (Pseudomonas aeruginosa, E. coli, Klebsiella pneumoniae, Enterobacter Sensors 2011, 11                                       
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aerogenes, Proteus vulgaris, S. aureus, Streptococcus pneumoniae, E. faecalis, Candida albicans, and 
Aspergillus fumigatus) using an electronic nose. 
The development of microbial discrimination and classification of pathogenic bacteria by e-nose 
analysis of biological fluids of diseased patients also has been studied. Chandiok et al. [121] diagnosed 
bacterial vaginosis by e-nose analysis of vaginal swabs of 68 women attending a genito-urinary clinic. 
The conventional sensing approach was based on pH change, presence of clue cells, visual analysis of 
vaginal discharge, and human perception of amine-odor after addition of KOH. Hay et al. [439] 
dramatically improved the accuracy of the same pathological diagnosis using a commercially available 
electronic nose in two separate trials. The e-nose increased the accuracy and specificity of the 
diagnosis by 76–81% compared with Amsel criteria, and 77-83% compared with Gram-stain tests. 
Lykos et al. [254] tested an electronic nose prototype designed and assembled by undergraduate 
students of the Illinois Institute of Technology on artificially-inoculated human blood cultures. After 
12 to 36 hours incubation, the electronic nose could successfully distinguish between different bacteria 
species (E. coli,  Pseudomonas aeruginosa,  S. aureus and E. faecalis) causing bacteremia and 
septicemia. This was an improvement over conventional subculturing procedures done on diagnostic 
plate media. Fend et al. [188] did blood analysis with an electronic nose to monitor and quantify 
dialysis dosage in patients undergoing regular renal dialysis following kidney failure. The electronic 
nose was capable of discriminating between pre-dialysis from post-dialysis blood. This tool could be 
used for on-line dialysis monitoring and other potential applications as pathogen sensors [440]. 
6.4. Diagnosis of Local and Systemic Microbial Infections 
Aathithan et al. [258] developed the Osmetech Microbial Analyzer (OMA) e-nose, an automated 
headspace analyzer fitted with a novel CP sensor array, for screening clinical urine specimens for 
bacteriuria by sampling urine headspace and multiple-detector PCA. The OMA distinguished 
artificially-infected urine samples from sterile controls in 534 clinical urine specimens, of which 
21.5% had significant bacteriuria (containing >105 CFU of bacteria/ml). The accuracy and specificity 
of the OMA compared with conventional culture were 83.5 and 87.6%, respectively and this system 
was considered a promising automated system for rapid routine screening of urine specimens. 
6.5. Progress of Healing, Physiological Monitoring, and Cellular Signaling 
Wounds are injuries to body tissues caused by diseases, processes or physically-damaging events 
such as burns, punctures, lacerations, ulcers or surgical procedures. Wounds can become infected 
when microorganisms from the environment enter the open wound and multiply, sometimes leading to 
severe symptoms. The standard techniques for microbiological detection are surface swabbing to 
assess superficial infections and biopsies for deeper wounds which are invasive. Byun et al. [441] 
recently proposed a novel method for monitoring open wounds by means of an experimental e-nose 
containing a sensor array composed of commercially-available MOS sensors fabricated by Figaro 
(TGS 2602, TGS 2610), Japan, and experimental SnO2-based thin film MOS sensors doped with Au, 
Cr, or WO developed by INFM-CNR, Italy and the Semiconductor Physics Institute, Lithuania. Initial 
data indicated that infected patients could be distinguished from uninfected patients, but the system is 
currently being validated on a larger number of patient samples. Tian et al. [442] used a gas sensor Sensors 2011, 11                                       
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array with six MOS sensors and one electrochemical gas sensor to identify seven species of pathogens 
common in wound infections in vitro. All seven pathogens were correctly identified and discriminated 
with an accuracy of 100% with this e-nose system. 
Halitosis or bad breath has been shown to be due to various volatile sulfur compounds (VSCs), such 
as hydrogen sulfide, methyl mercaptan, and dimethyl sulfide produced by bacterial metabolism. Oral 
pathologic odor is caused by disease, pathological conditions and oral tissue malfunction. The 
organoleptic test has been used by medical practitioners for the evaluation of halitosis, but this test is 
somewhat subjective. Thus, the development of a halitosis measurement system for objective and 
reliable human breath evaluation is required. Commercially-available portable sulfide monitors using a 
gas sensor have insufficient sensitivity and selectivity to measure many VSCs. In 2004, Ito et al. [443] 
proposed a method for discriminating VSCs (hydrogen sulfide, methyl mercaptan, and dimethyl 
sulfide) using a Quartz Crystal Microbalance (QCM) sensor array combined with a preconcentrator. 
The results of PCA indicated that three types of VSCs were separated using the sensor array output 
pattern. 
Tanaka et al. [425] tested the capability of the FF-1 electronic nose (composed of a   
pre-concentrator and an array of 6 MOS sensors) to discriminate the odors present in human breath of 
49 patients complaining of oral malodor and 29 control subjects without halitosis. Tanaka’s work was 
continued by Nonaka et al. [444] who tried to express the clinically oral malodor intensity as an 
absolute value. The same e-nose was used and the absolute value of the malodor intensity was 
expressed as the vectorial sum of the malodor intensity of each category of gas. Yamada et al. [445] 
also used the same odor-sensing e-nose to assess the presence of putrescent odor produced in 
association with necrosis of dental pulp resulting from the presence of root canal bacterial infection. 
The odor from each mouth root canal of 39 patients was expressed as absolute odor by use of the 
diagnostic software called ASmell2. Pennazza et al. [446] focused on the design of breath-sampling 
procedures to optimize halitosis measurements and evaluate the threshold limits of the electronic nose 
towards biomarker compounds that play a key role in oral malodor manifestations.  
Saraoğlu et al. [447,448] addressed the problem of anesthesia levels during surgeries. The effects of 
applied anesthesia on a patient, known as the depth of anesthesia, can change according to the 
chemicals used and characteristics of the patient. During a surgical operation, the depth of anesthesia 
is determined by an anesthetist, who has to continuously monitor and measure patient sensitivity and 
dosage level applied. A calibration defect or malfunction in the vaporizer equipment can bring the 
patient to a life-threatening critical condition. In this study, a prototype QMB electronic nose using 
sensors coated with phthalocyanine was developed with high sensitivity to sevoflurane, the anesthetic 
agent used in the study. The results of the first experiment indicated a success rate of 95% in the 
prediction of the effective anesthetic dose level applied. A latter experiment revealed a means for 
effectively reducing the delay in QMB response from 5 to 15 minutes down to 100 seconds. 
6.6. Organ Transplant Rejection 
Phillips et al. [192] evaluated a breath test for oxidative stress (based on breath alkanes) in heart 
transplant recipients and a mathematical model for predicting the probability of grade 3   
heart-transplant rejections. The test was 100% accurate for grade 3 heart transplant rejection when a P Sensors 2011, 11                                       
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value was ∃0.98, and 100% specific when the P value was #0.058. The alkane biomarkers were 
specific for the indication of oxidative stress related to heart allograft rejections. The potential use of 
e-nose evaluations and determinations of other types of organ transplant success based on breath or 
urine volatiles will be further explored in the coming years.  
6.7. Cancer Detection 
More than 20 years ago, Gordon et al. [449] and O’Neil et al. [293] suggested that the exhaled air 
of lung cancer patients could contain specific VOCs that could be associated with this disease. The 
very early diagnosis and prompt treatment of lung cancer has been shown to dramatically shift the  
5-year survival rate from 14% to 48% [450]. The same results were obtained by Phillips et al. [64] 
who conducted GC-MS analysis of the exhaled breath of 108 lung cancer positive and negative 
patients and found 22 VOCs to be useful biomarkers of lung cancer. 
Di Natale et al. in 2003 [283] probably first suggested the possibility of using an electronic nose for 
the early diagnose of lung cancer. They postulated that the bouquet of VOCs containing lung cancer 
biomarkers in the exhaled breath could be recognized and discriminated by means of an electronic 
nose with 10 QMB sensors. The results with 42 diseased and 18 non-diseased volunteers showed that 
this e-nose could correctly classify 100% of lung cancer patients, and 94% of healthy controls. 
Chen et al. [295] proposed a new prototype of an electronic nose based on a virtual array of SAW 
sensors with the sensor output analyzed using an image-recognition method and an improved ANN. 
This e-nose was able to detect eleven VOCs that were validated as markers of lung cancer, and 
subsequently obtained good preliminary results with hospitalized patients.  
Machado et al. [234] tested the Cyranose 320 electronic nose on 14 individuals with bronchogenic 
carcinoma and 45 healthy control subjects to identify and discriminate between diseased and   
non-diseased patients. They also applied supporting vector-machine analysis of smell prints of exhaled 
breath to create a cancer-prediction model using a training set of exhaled gases from diseased and 
healthy controls. The results demonstrated effective discrimination between the two sets of samples. In 
the validation study, the electronic nose had almost 72% accuracy and 92% specificity for detecting 
lung cancer. The positive and negative predictive values were 66.6% and 94%, respectively. 
Dragonieri et al. [451] was able to discriminate between patients affected by non-small cell lung 
cancer, chronic obstructive pulmonary disease, and healthy controls by means of the Cyranose 320 
electronic nose. The results showed that the smell prints of patients with lung cancer could be 
discriminated from subjects with Chronic Obstructive Pulmonary Disease (COPD) and healthy 
controls. The breath of patients with chronic obstructive pulmonary disease, often associated with the 
development of the lung neoplasm, are now known to contain VOCs that are distinct from those in 
patients with lung cancer. 
D’Amico et al. [452] investigated the possibility of using an electronic nose as a means of 
distinguishing lung cancer from other lung diseases. This study involved 98 patients grouped into three 
sample classes: those with non-small cell lung cancer, other lung diseases and healthy controls. The 
QMB gas sensor array utilized was the latest prototype version of the artificial olfaction system 
developed at the University of Rome “Tor Vergata” based on eight QMB sensors coated with 
metalloporphyrins. The discrimination between the control group and lung cancer was 85% accurate Sensors 2011, 11                                       
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with a specificity of 100% and negative predictive value of 90%, due to four false negatives, and a 
positive predictive value of 100% with no false positives. The separation between cancer-affected 
patients from individuals having other lung diseases was as followings: 86% of correctly classified 
patients were determined with an accuracy of 92.8% and 78.6% for lung cancer and the other lung 
diseases, respectively.  
Previously, the investigation of VOCs identified from the exhaled breath of lung cancer patients has 
revealed important biomarkers for this disease. However, biomarkers have not yet been identified for 
many other types of cancer. This problem is primarily due to the difficulty in determining which 
specific VOCs, among a vast myriad of possible compounds detected using GC-MS analysis, that is 
most correlated with a specific cancer type. Electronic noses promise to be very useful noninvasive 
tools for cancer detection because they are sensitive and relatively inexpensive for diagnostic 
applications and are able to discriminate between aroma signatures consisting of hundreds of unknown 
compounds. One of the first studies to investigate the possibility of discriminating between different 
tumor cell lines in vitro was performed by Gendron et al. [175]. They reported on the in vitro 
discrimination of tumor cell lines by use of an electronic nose. Cells from both tumor (adenocarcinoma, 
squamous cell carcinoma, mesothelioma) and normal healthy cell lines were suspended in saline 
solution and analyzed by the Cyranose 320 e-nose that distinguished between cancer cell lines derived 
from skin lesions. This same e-nose was later demonstrated to have good sensitivity towards VOCs 
emitted from skin portions of patients affected by melanomas. 
The abnormal metabolisms of tumor cells cause alterations in the chemical composition of VOCs 
released from affected cells, resulting in differences in the aroma patterns of headspace volatiles which 
can be distinguishable by an electronic nose. In 2008, D’Amico et al. [453] tried to identify melanoma 
patients by measuring the VOCs emitted from dark skin lesions using the University of Rome “Tor 
Vergata” QMB e-nose prototype on 40 individuals. The results showed that this electronic nose 
correctly discriminated between diseased and healthy controls with an accuracy of about 80%, similar 
to the performance of more labor-intensive and time-consuming diagnostic methods. 
Brain cancer was investigated by Kateb et al. [193] who assessed the possibility of detecting and 
differentiating between the aroma signatures of liver and heart organ tissue (from chickens) and 
differences between tumor cell lines of human glioblastoma and human melanoma tumors. The Jet 
Propulsion Laboratory’s electronic nose, based on 16 sensors with uniquely coated polymer-carbon 
black composite films, was able to distinguish between the two types of organ tissues and between the 
two types of tumor cell lines. In a similar study, Horvath et al. [454] used an e-nose to discriminate 
between different VOC signals emitted by ovarian carcinoma and normal tissues. This method showed 
an accuracy of 100% based on 15 samples of each tissue type. Bernabei et al. [455] investigated the 
possibility of an early and non-invasive diagnosis of urinary tract cancers using an electronic nose. 
Measurements of urine headspace VOCs were performed by means of a QCM e-nose with eight quartz 
crystal microbalance sensors coated with different metalloporphyrins. A total of 113 patients affected 
by various urological pathologies were tested and e-nose data were processed via PCA and 
discriminant analysis using partial least squares. Discrimination and differentiation between healthy 
and ill individuals was achieved between patients with prostate and bladder cancer. The headspace of 
urine samples of patients with urinary tract cancer was different from that of healthy individuals. Sensors 2011, 11                                       
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These preliminary results confirm a correlation between urine headspace and urological pathologies, 
enhancing the future possibility of performing early cancer diagnoses. 
6.8. Prosthetic e-Nose Interface Applications 
Biddiss and Chau [200] utilized a Conductive Polymer (CP) e-nose as a sensor and actuator for the 
control of hand prosthetic applications. This is a very good example demonstrating the many 
possibilities for interfacing e-nose components with prosthetics for biomechanical applications.   
Hong et al. [190] evaluated an implanted piezoelectric floating-mass transducer for sensor-
neurological interfacing for the correction of hearing loss. Many other e-nose integrations with other 
prosthetic devises and healthcare applications are under development and will no doubt be 
forthcoming in the future as new e-nose combinations with other mechanical-aid devices are 
conceptualized by biomechanical engineers. 
7. Conclusions 
The biomedical field is growing at such a rapid rate that the development of new e-nose 
applications in this field also is accelerating due to increased emphasis on research and development 
(R&D) of these sensor systems by companies that build diagnostic equipment for the healthcare 
industry. The increasing demand for problem solutions to many and varied medical needs of modern 
societies has increased the need for cheap, rapid, and reliable diagnostic systems that work in   
real-time. The increasing emphasis of research priorities and funding for the development of new  
e-nose technologies in the medical industry has been related to the higher cost of detection instruments 
needed for disease diagnoses, the increasing demand for such instruments in medical hospitals and 
research facilities, the greater availability of funding for instrument purchases, and the higher visibility 
of biomedical needs and new diagnostic discoveries [8]. The shift in emphasis of R&D activities of 
commercial companies that develop electronic noses also has been profit-motivated. Electronic nose 
instruments developed for diagnostic medical applications often are considerably higher priced and 
more lucrative for commercial development than for other industries. 
The design of sensory systems found in nature often has served as model systems for the creation of 
instrumental olfactory systems that have led to some astonishing and innovative applications. The 
mammalian olfactory system is one of the most incredible natural systems that have been applied to 
machine olfaction and to olfactory diagnosis [456]. Thus, the inherent competent design of natural 
living systems often provide very effective models for the design of electronic noses for numerous 
sensing applications with both physiological and mechanical interactive components [132]. The 
development of bio-inspired devices, designed by the mimicry of natural biosensors, will no doubt 
lead to exciting new interactive and monitoring biomechanical e-noses that serve multiple bodily 
functions for individuals with impaired physiological systems. New sensor types and sensor coatings 
allow specialization and specificity in chemical detections. Reducing the number of detectors in the 
sensor array reduces the cost of portable e-noses needed for clinical and extraclinical diagnoses. The 
selection of sensor arrays by the utilization of large libraries of sensor types with different sensor 
coatings (sensitive to specific classes of VOCs) will facilitate the building of custom-designed e-noses 
for specific applications. Sensors 2011, 11                                       
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Advances in information technology and satellite communication systems, combined with novel 
intelligent sensors like e-noses, should result in better management of epidemic diseases such as 
tuberculosis (TB), autoimmune deficiency syndrome (AIDS), and other major diseases responsible for 
current world pandemics [457]. Thus, applying e-nose technologies should lead to better global disease 
control and reduced risk of spreading major infectious diseases around the world. By combining e-
nose technologies with other advanced smart and adaptive engineering systems, it should be possible 
to create new tandem or interfaced systems with synergistic capabilities for disease diagnoses and 
other biomedical applications [458]. For example, electronic nose-related technologies using pattern 
recognition algorithms have been used in combination with blood flow spectra for disease 
classification in limb arteries [459], and for detection of toxin exposure associated with smoking [460]. 
Many other potential opportunities for combining e-nose technologies with other   
chemical-detection and mechanical devices such as analytical chemistry instruments [8], electronic  
tongues [131,138,461], biosensors [129-131,462-466], hydrogels [467,468], porous silicon [140,469], 
microbead arrays [137], various nanotechnologies [182,197], neurochips [134], mechanical   
drug-delivery systems [136,199,470,471], and image-analysis devices [472,473] have been emerging 
in recent years. The possibilities for the future development of entirely new electronic-noses and e-
nose tandem devices for the healthcare industry are enormous. This potential will continue to increase 
as new innovative e-nose technologies are developed and become adapted for healthcare and 
biomedical applications. 
Continuing improvements in effective clinical healthcare practices as we proceed into the 21st 
century increasingly will require that we make patient-treatment decisions based on multi-source 
information inputs, such as patient history, thorough physical examinations, symptomology, and 
physiological and biochemical real-time (rapid) diagnostic tests using e-nose or similar electronic 
devices. A final real-time confirmation of patient status and diagnosis using fast and reliable electronic 
devices is a very useful and necessary step to avoid mistakes in applying proper and appropriate 
patient treatments. Such a comprehensive approach to healthcare treatments previously has not been 
widely implemented hitherto and most current hospital and family clinic healthcare policies still use 
and rely on a “one target—one result” approach [456]. These non-confirmational practices will 
eventually be replaced as higher public expectations of medical standards and practices required more 
stringent procedures to not only avoid treatment mistakes, but also maintain favorable public relations 
and good reputations of healthcare institutions, and minimize cases of malpractice which greatly 
contribute to higher healthcare costs. The addition of electronic noses to help confirm patient status 
and diagnosis will contribute greatly to the development of more stringent criteria and practices for 
confirmation of diagnostic determinations prior to application of appropriate treatments. 
There are several current limitations that have hindered the development of e-nose medical 
applications in the medical industry. One major problem is that there has not been sufficient trial  
in-hospital testing of e-nose instruments to determine the capabilities, feasibility and performance of 
these instruments for specific tasks (applications) within the operating practices of hospitals and other 
medical-care facilities. The slow willingness of some doctors and medical-services personnel to test 
and adopt new technologies, due to resistance to change from traditional methods, the existence of 
prejudices and biases against the capabilities of e-nose instruments, have precluded adequate efficacy 
testing and feasibility studies. Some hindrances to the advancement of e-nose applications have to do Sensors 2011, 11                                       
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with the difficulty, often experienced by instrument developers, in identifying specific biomedical 
applications that would be the most feasible and useful in medical practice. This requires effective and 
specific input from medical practitioners on a regular basis. Many new medical applications have been 
developed and are in current use with very good e-nose efficacy data already available. Nevertheless, 
much more research is needed to develop and take full advantage of e-nose instruments to bring them 
to the full potential of capabilities for healthcare applications. With a vast amount of literature now 
available to demonstrate the theoretical and practical feasibility of using electronic noses in many 
diverse medical applications, the trick now will be to go the extra distance to begin to fine-tune these 
technologies for many practical and specific applications. This will require cooperative efforts and 
informative exchanges between researchers and medical practitioners. Once these difficulties and 
logistics are resolved, electronic-nose devices should be capable of solving many medical diagnostic 
problems and serving many of the future needs of the medical industry that have yet to be discovered. 
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